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Colorectal cancer (CRC) is the third most common cancer and the second main cause of cancer
mortality worldwide. The colorectum and the small bowel are part of a continuous passageway called
the gastrointestinal (GI) tract, however, the cancer incidence varies greatly between these two organs.
Although the small bowel constitutes three quarters of the length of the GI tract, only 3% of GI cancers
are located in the small bowel. These cancers develop due to both somatic and inherited germline
mutations. Thus, characterizing the genetic events that drive tumorigenesis is crucial to provide ways
to improve prevention and clinical management of the disease. The general aim of this thesis was to
gain new insights into the molecular genetic backgrounds of CRC and small bowel adenocarcinoma
(SBA).
The first aim of the thesis was to characterize the somatic mutation patterns of the AT-Rich Interaction
Domain (ARID) family genes in CRCs with microsatellite instability (MSI). Approximately 15% of
CRCs display MSI which arises due to a defective DNA mismatch repair system. These tumors
accumulate a high number of mutations, especially small insertions and deletions in repetitive
genomic areas called microsatellites. The ARID gene family comprises 15 members, including a
known tumor suppressor gene ARID1A. We utilized exome sequencing data of 25 MSI CRCs and
their corresponding normal tissues and identified 12 of the ARID genes to display mutations with a
frequency of 4-52%. Four genes were selected for further analysis in 21 additional MSI CRCs. We
found that, in addition to ARID1A, also ARID1B, ARID2, and ARID4A were frequently mutated and
might play a role in MSI CRC. However, additional studies are warranted to further scrutinize the
function of these mutations in MSI CRC genesis.
The second aim of the thesis was to identify novel oncogenes in MSI CRC. These tumors represent a
sensitive system for studying the generation and selection of oncogenic mutations. In contrast to many
reported MSI target genes, few oncogenes are known in MSI CRC and they often display specific
mutation hotspots. Thus, we used the exome sequencing data of 25 MSI CRCs and their
corresponding normal tissues to search for genes with recurrent somatic missense mutations. We
identified 33 novel candidate oncogenes of which the following fourteen genes displayed hotspot
mutations also in the validation set of 254 MSI CRCs: ANTXR1, CEP135, CRYBB1, MORC2,
SLC36A1, GALNT9, PI15, KRT82, CNTF, GLDC, MBTPS1, OR9Q2, R3HDM1, and TTPAL. This
work revealed a variety of novel recurrent candidate oncogene mutations that might potentially be
used to develop personalized therapies. Further research is still needed to confirm their pathogenic
role and detailed function in tumorigenesis.
The third aim of the thesis was to study the genetic overlap within synchronous CRCs (SCRCs).
Approximately 4% of CRC patients display multiple simultaneous primary cancers in the colorectum.
Understanding whether SCRCs within a patient are genetically similar or distinct is essential when
designing personalized treatments. Exome sequencing data of 23 SCRC pairs and their corresponding
healthy tissues revealed that the paired tumors shared a maximum of only a few somatic mutations.
This indicated that the tumors have independent origins. Furthermore, paired tumors favored different
somatic mutations in known CRC genes and signaling pathways. Variation was observed among
clinically relevant genes, such as the discordant KRAS mutation status in a quarter of patients. Tumors
within pairs also displayed variation in their mutational signature content suggesting that, regardless
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of the shared environment, some pairs might have undergone different mutational processes. Finally,
by analyzing immune cell counts, we observed that the intratumor immune response varied within
most tumor pairs. This was not explained by mutation burden or clinicopathological variables.
Overall, this work revealed major diversity within SCRCs and highlights the need to evaluate all
synchronous lesions within an individual for optimized therapeutic approach. Additional studies are
still required to further elucidate the reasons underlying tumor multiplicity.
The fourth aim of the thesis was to characterize the somatic mutation content in SBA. Due to its rarity,
knowledge on the genetic background of SBA has remained somewhat elusive. We conducted the
first large exome sequencing effort of 106 population-based SBAs representing all three small bowel
segments. This work revealed significantly mutated genes previously associated with SBA (TP53,
KRAS, APC, SMAD4, and BRAF), as well as novel candidate drivers, such as ACVR2A, ACVR1B,
BRCA2, and SMARCA4. We identified clear mutation hotspot patterns in ERBB2 and BRAF.
Interestingly, we observed no V600E mutations, the most common BRAF mutation hotspot in CRC.
Other clinically relevant aspects included mutations in ERBB family genes in over a quarter of SBAs
as well as mutations in multiple genes that could predict anti-EGFR treatment resistance. We
performed the first comprehensive mutation signature analysis on SBA that highlighted four
signatures: 1A, 6, 17, and U2. Comparison of the three small bowel segments unveiled some variation
in tumor characteristics. Further studies are needed to robustly clarify these differences and their
clinical relevance. This comprehensive characterization provided further evidence that SBA is a
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REVIEW OF THE LITERATURE
1. Etiology of cancer
Cancer refers to a large group of diseases that share the ability for abnormal growth and proliferation
of cells, regardless of normal cell control mechanisms. It can originate from most cell types and
organs. Adenocarcinoma is the most common cancer type and it arises from columnar epithelial cells
found e.g. in the lining of the gastrointestinal (GI) tract. Cancers are characterized by their ability to
invade locally, disseminate from the primary site, and metastasize to distant organs. This separates
them from benign tumors that, by definition, are localized and non-invasive. Benign tumors can,
however, also become clinically relevant if they grow enough to create pressure to the surrounding
tissues or produce abnormal quantities of hormones.
Cancer is one of the leading causes for morbidity and mortality worldwide. In Finland, over 34,000
cancer cases were diagnosed in 2017 and slightly under 12,800 patients died of it (Finnish Cancer
Registry, https://syoparekisteri.fi/tilastot/syopa-2017-raportti/). Most cancer related deaths are due to
metastatic disease1. Today, nearly two thirds of the cancer patients are cured (www.cancer.fi). In
Finland, the most common primary sites for cancer are prostate, colorectum, and lung in males and
breast, colorectum, and lung in females (www.cancerregistry.fi/statistics/cancer-statistics/).
Cancer is thought to originate from a single cell. Accumulation of mutations in deoxyribonucleic acid
(DNA) together with epigenetic changes provide a cell growth advantage over the adjacent cells and
the ability to undergo clonal expansion2,3. Thus, cancer is considered as a genetic disease and
tumorigenesis an evolutionary process comparable to Darwinian natural selection. During the
expansion of neoplastic cell population, individual cells obtain different mutations during each cell
division leading to branched evolution where some subclones proliferate faster than other lesser fit
clones. This produces genetic heterogeneity within the tumor as well as metastasis, between different
metastatic lesions within a patient, and between tumors of each individual4. Tumor growth and its
spread to distant sites is further advanced by complex interplay between neoplastic cells and their
surrounding microenvironment. Cancer can be considered as a complex dynamic environment that
contains heterogeneous populations of cancer cells in contact with the surrounding stroma and its
many types of cells, such as immune cells, fibroblasts, endothelial cells, pericytes, and smooth muscle
cells5.
Features that a cell needs to obtain to evade the mechanisms that control cell growth and to reach a
malignant state are described as the hallmarks of cancer5,6. These characteristics include sustaining
proliferative signaling, evasion of growth suppressors, resisting cell death, enabling replicative
immortality, inducing angiogenesis, and activating invasion and metastasis. There are two additional
hallmarks that enable the above-mentioned hallmarks, namely genome instability and tumor-
promoting inflammation. Finally, two emerging hallmarks have been added to the list:
reprogramming energy metabolism and evasion of immune destruction.
The development of a solid tumor, from a benign local lesion into a malignant cancer, has been
estimated to take up to several decades7. Due to accumulation of mutations over the course of time,
age is considered as a key risk factor for cancer. Cancer risk is also influenced by lifestyle and
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environmental factors which vary between different cancers. The most common preventable lifestyle
risk factors include smoking, obesity, diet, and alcohol consumption. Environmental risk factors
entail ultraviolet and ionizing radiation and certain infectious agents, such as human papillomaviruses
that predispose to many cancers, most commonly cervical cancer, and Helicobacter pylori that
predisposes to gastric cancer8,9. Hereditary factors, that is genomic changes in the germline of an
individual, are also recognized as important contributors to many common cancers.
2. Genetic and epigenetic features in cancer
Mutations in the DNA are either inherited or acquired. Inherited mutations exist in the fertilized egg
and therefore found in all cells of an individual. Some of these germline mutations increase the risk
of developing cancer. This contribution in risk varies greatly between mutations. Hereditary cancer
refers to cases that carry a germline mutation that confers increased susceptibility to cancer, whereas
cancers that arise without any known germline contribution are called sporadic. Contribution of
predisposing mutations can vary between different cancers. As an example, familial adenomatous
polyposis (FAP) patients with a germline mutation in the gene APC Regulator Of WNT Signaling
Pathway (APC) present more often cancers in the colorectum than in the small bowel10.
Acquired, also called somatic, mutations are alterations that gather during one’s lifetime and can
occur in all dividing cells, both normal and malignant11. The median somatic mutation frequency in
a normal cell has been estimated to be 2.8x10-7 per base pair12. These mutations arise either from
exposure to endogenous and exogenous mutagens or in DNA replication during mitotic cell
division11. The changes include base substitutions, deletions or insertions of bases, copy number
alterations, and rearrangements3. Base substitutions can be further divided into nonsynonymous and
synonymous, depending on whether they result in an amino acid change or not. In a normal cell, most
mutations are corrected by DNA repair mechanisms. Mutations that are not repaired are passed onto
the following daughter cells (Figure 1). Due to the accumulation of mutations in the course of time,
the risk of developing cancer increases with age. It has been estimated that approximately 29% of
mutations in cancers are due to environmental factors, 66% are attributable to DNA replication errors,
and 5% are due to hereditary causes13.
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Figure 1. The development of a single cell lineage to a malignant tumor. A cancer cell develops via a
lineage of mitotic cell divisions from the fertilized egg. Somatic mutations accumulate over a lifetime due to
intrinsic and environmental factors. Most of these mutations are passenger events, whereas a small subset are
driver mutations that confer selective growth advantage. Chemotherapy resistant mutations often predate the
cancer treatment and can cause relapse afterwards. Adapted by permission from Macmillan Publishers Ltd:
Nature (Stratton et al. 2009), copyright (2009).
Mutations that contribute to obtaining cancer hallmarks, bring selective advantage to the cell, and
thus drive tumorigenesis are called driver mutations4. It has been estimated that only two to eight
such driver events are required for cancer development4,14. Mutations accumulate through cell
division and once several driver genes are defective, cancer will develop. Of note, some mutations
are only needed at later stages of tumor evolution to achieve resistance to chemotherapy. Whereas,
mutations that do not confer selective growth advantage and have not been subject to selection are
called passenger mutations11. Most of the mutations found in cancer are passenger events that have
occurred by chance in a progenitor cell that underwent clonal expansion.
Cancer driver genes are classically divided into oncogenes and tumor suppressors. Oncogenes can
promote tumor growth through activating mutations. Tumor suppressor genes, on the other hand,
achieve their tumorigenic effect by mutations that inactivate the gene function. Some cancer driver
genes, such as Tumor Protein P53 (TP53) and KRAS Proto-Oncogene (KRAS), are frequently mutated
in a variety of cancers, whereas other genes are specific to certain tumor types15. It has been suggested
that tumorigenesis is driven by 12 main signaling pathways that regulate cell survival, cell fate, and
genome integrity4. Known cancer genes can be associated with one or more of these pathways.
Classification of genes into pathways provides better understanding why certain driver mutations are
essential to cancer, how mutations in different genes can have similar effect on tumorigenesis, and
helps direct cancer therapy development.
2.1. Oncogenes
Proto-oncogene is the normal equivalent of an oncogene. When proto-oncogenes are altered, they are
transformed into oncogenes that can drive tumorigenesis. Usually these changes act in a dominant
manner, that is, mutation in one allele is enough to provide selective growth advantage to the cell.
Oncogenes encode proteins that regulate cell proliferation and survival. These include growth factors
and their receptors, transcription factors, chromatin remodelers, signaling molecules, and apoptosis
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regulators16. Gain-of-function defects in oncogenes are typically point mutations that reoccur at one
or few amino acid positions, called mutation hotspots. In addition, activation can happen through
gene amplification and chromosomal rearrangements. Causative germline mutations are only rarely
found in oncogenes due to their embryonic lethality.
First somatic point mutation identified in cancer was HRAS harboring recurrent missense mutations
in codon 1217. HRAS, together with KRAS and NRAS, are members of the RAS family that encode for
small GTPases which are involved in transducing signals within the cell through mitogen-activated
protein kinase (MAPK) signaling. When mutated at codons 12, 13, or 61, resulting proteins remain
in an active state inducing continuous cell growth16. KRAS is considered as the most commonly
mutated oncogene18. Another well-known oncogene displaying activating hotspot mutations is B-Raf
Proto-Oncogene (BRAF), usually harboring a mutation at codon V600. BRAF acts downstream of
RAS in the MAPK/extracellular signal-regulated kinase (ERK) pathway and when aberrantly
activated, phosphorylates downstream targets constitutively leading to aberrant cell growth19. BRAF
mutations are found in a variety of cancers, such as melanoma, non-small cell lung cancer, thyroid,
hepatocellular, and colorectal cancer (CRC).
Chromosomal rearrangements activating oncogenes are usually translocations that combine proto-
oncogenes with an enhancer or form a chimeric protein product. The first evidence that cancer is
caused by somatic genetic changes appeared from Burkitt lymphoma studies where MYC Proto-
Oncogene (MYC) was observed to translocate to three alternative loci that harbored an
immunoglobulin gene with an enhancer element, thus activating the juxtaposed MYC20–22. Whereas,
the fusion of ALL1 with a variety of proteins is a well-known example of a chimeric protein formation
underlying acute myelogenous leukemia and acute lymphoblastic leukemia16. Translocations are also
encountered in solid tumors, such as the TMPRSS2-ERG gene fusion commonly found in prostate
cancer23. Amplification that results in an increased expression of an oncogene is often seen in MYC
and RAS family genes in various cancers. Other targets for amplification are Erb-B2 Receptor
Tyrosine Kinase (ERBB) family genes, such as Epidermal Growth Factor Receptor (EGFR, also
known as ERBB1) and ERBB2 (also called Human Epidermal Growth Receptor 2 (HER2)). EGFR
amplifications are encountered e.g. in glioblastoma and head and neck cancers and ERBB2 in breast
cancer.
Oncogenic proteins can be targeted by small molecules or monoclonal antibodies16. They are feasible
therapy targets since cancer cells are dependent on the oncogene products, making them more
sensitive to therapy compared to normal cells. One example of such a drug is a monoclonal antibody
against HER2, trastuzumab, that is effectively used in breast cancer overexpressing HER2.
2.2. Tumor suppressor genes
In normal cells, tumor suppressors function to keep the cell differentiation stable by, for example,
restraining growth, proliferation, and passage through the cell cycle24. Tumor suppressors are
traditionally divided into two categories, gatekeeper and caretaker genes25. Gatekeepers limit tumor
initiation directly by inhibiting growth or promoting death, whereas caretakers maintain genome
integrity. Tumor suppressor genes are often inactivated by protein-truncating mutations coupled with
allelic loss of the second allele or by promoter hypermethylation26. As opposed to oncogenes,
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mutations in tumor suppressor genes are typically scattered along the gene. Inactivation of tumor
suppressor genes can lead to either reduced protein activity or a complete loss of function.
Tumor suppressor genes are recessive in nature. This means that usually both alleles must be
inactivated to result in selective growth advantage for the cell. Patients carrying a germline mutation
in a tumor suppressor gene, have an increased risk of cancer since only one additional somatic
mutation is needed for biallelic loss of function. This two-hit hypothesis was first proposed by Alfred
Knudson in early-onset retinoblastoma, a tumor of the retina27. Fifteen years later, RB1 - the gene
responsible for the disease, was discovered28. RB1 is a negative regulator of the cell cycle and
represents a classic example of a gatekeeper gene. When both alleles of the gene are targeted, it drives
cell progression in a direct manner25.
Exceptions to the classical two-hit hypothesis also exist. In some cases, the inactivation of one allele
of a tumor suppressor is enough to promote tumorigenesis, termed “haploinsufficiency”29. Sometimes
this single-copy loss may even be preferred in tumor evolution. One example of this is a
haploinsufficient loss of Phosphatase And Tensin Homolog (PTEN) which, while providing growth
advantage, avoids triggering p53-dependent senescence that complete loss of PTEN would
promote30,31. Another exception is called a dominant-negative effect, that is, when one mutated gene
copy interferes with the function of the normal protein produced by the wild-type allele. For example,
in TP53, the best-known tumor suppressor, mutation in one allele may contribute to the
oligomerization of the mutant and wild-type protein32.
Caretakers, also called “stability genes”, include genes that encode for mitotic checkpoint and DNA
repair proteins, such as BRCA1, BRCA2 DNA Repair Associated (BRCA2), ATM Serine/Threonine
Kinase (ATM), and MutL Homologue 1 (MLH1) together with other mismatch repair (MMR)
genes25,33. Their inactivation promotes tumorigenesis indirectly by leading to increased mutation rate
across the genome including genes that provide selective growth advantage. Germline mutations in
the DNA repair genes BRCA1 and BRCA2 are found in hereditary breast cancer and ATM mutations
in ataxia telangiectasia. An example of epigenetic inactivation of such genes is biallelic promoter
hypermethylation of MLH1 seen in sporadic CRC34.
Some tumor suppressors, such as TP53, might harbor features of both classes35. TP53 is categorized
as a gatekeeper due to its direct involvement in cell cycle regulation and cell proliferation. It also
possesses caretaker features as it functions in the DNA damage response. Another example is AT-
Rich Interaction Domain 1A (ARID1A), recognized as one of the most commonly mutated genes in
cancer15. ARID1A is a chromatin remodeler and involved in cell cycle regulation36. It may also
present features of a caretaker in the prevention of genomic instability37. ARID1A is one of 15 ARID
domain-containing proteins that bind to DNA either specifically at AT-rich sites or in a non-specific
manner38. In general, the ARID proteins partake in many biological processes, such as regulation of
development and gene expression.
A third category of tumor suppressors, the landscapers, has also been introduced. This includes genes
that do not have a direct impact on cell growth. Instead, they promote neoplastic transformation of
cells by creating an abnormal stromal environment39. Compared to oncogenes, developing therapies
which target tumor suppressors is much more difficult since the replacement of the defective protein
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would be required to restore its normal activity. However, another promising approach is to target the
signaling pathways controlled by these genes40.
2.3. Genomic instability
Genomic instability occurs in most cancers and refers to chromosomal instability (CIN) or increased
mutation frequency in the DNA41. CIN is the most common type of genomic instability in cancer and
is characterized by an increased rate of structural and numerical changes in chromosomes. Structural
variations include insertions, deletions, duplications, inversions, translocations, amplifications, and
insertions of transposable elements. CIN can also cause aneuploidy through loss or gain of whole
chromosomes. Such changes can contribute to driving tumorigenesis by activating oncogenes and
inactivating tumor suppressors. Though the rate of chromosomal changes in tumors is elevated, the
point mutation rate is estimated to be similar to that of normal cells4. Processes underlying CIN are
not fully understood but it is thought to originate from various mechanisms, such as impaired mitotic
checkpoint function or cell-cycle regulation, that lead to missegregation of chromosomes42. CIN is
thought to occur early and to be a pivotal step in tumorigenesis43. Given that CIN influences various
steps in the initiation and development of a tumor, and may contribute to the development of
metastases, therapeutics targeting CIN could have a major impact in the improvement of clinical
outcomes44.
The increased rate of mutations can be due to a defective DNA MMR system. This is caused by
biallelic inactivation of one of the MMR genes (MLH1, MutS Homolog 2 (MSH2), MutS Homolog 6
(MSH6), or PMS1 Homolog 2 (PMS2)). When defective, MMR cannot repair the slippage errors made
by the DNA polymerase during DNA replication. This results in the accumulation of mutations,
mainly insertions and deletions in short repetitive DNA tracks called microsatellites. This
phenomenon is called microsatellite instability (MSI) and is encountered e.g. in CRC, gastric, and
endometrial cancer. The point mutation rate is also elevated in these tumors24. Another mechanism
to drive malignant transformation emerges from defective DNA proofreading enzymes, DNA
Polymerase Epsilon (POLE) and DNA Polymerase Delta 1 (POLD1), which leads to increased
frequency of point mutations in the DNA45,46. This ultra-mutated phenotype has been found in CRC
and endometrial cancer.
2.4. Epigenetic changes
In addition to genetic alterations, gene products can be affected through epigenetic modifications4.
Epigenetics refers to changes in gene expression occurring independent of changes in the underlying
DNA sequence. The cancer epigenome is characterized by changes in DNA methylation (such as
genome-wide hypomethylation or hypermethylation of gene promoters with CpG-islands), histone
modification, nucleosome positioning, and micro-ribonucleic acids (miRNAs)47. These changes can
result in silencing of tumor suppressors and activation of oncogenes and thus play an important role
in cancer initiation and progression. Epigenetic alterations can lead to inactivation of tumor
suppressor genes either independently or together with an inactivating genetic change. Therefore,
epigenetic changes can serve as the second hit required for cancer initiation according to Knudson’s
“two-hit” hypothesis. Since epigenetic alterations are potentially reversible, they make appealing
candidates for the development of targeted therapies.
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Chromatin structure defines how DNA is organized within a cell, influencing which areas are active
in a given time47. There are many mechanisms that allow compaction and decompaction of DNA.
One of such is Switch/Sucrose Non-Fermentable (SWI/SNF) complexes that regulate gene expression
by using the energy of ATP to remodel chromatin48. Mammalian SWI/SNF complexes contain a core
ATPase, either BRG1 or BRM, involved in nucleosome remodeling and other co-factors, such as
members of the ARID family, ARID1A, ARID1B, and ARID2. These complexes can be divided into
two broad categories based upon the presence of either one of the mutually exclusive ARID1A or
ARID1B subunits (BAF complex) or ARID2 and PBRM1 subunits (PBAF complex). The ARID
domain allows the proteins to bind to DNA. SWI/SNF complexes have been estimated as the most
frequently mutated epigenetic regulators in cancer49. These complexes are thought to have a
widespread role in tumor suppression. Of the genes encoding for the subunits, ARID1A is the most
frequently mutated in cancer48. Mutations in many of the other genes, such as SWI/SNF Related,
Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A, Member 4 (SMARCA4,
encodes for BRG1), PBRM1, ARID1B, and ARID2, have also been found in a variety of cancers49.
2.5. Inherited predisposition to cancer
Genetic susceptibility for cancer can be divided into three categories based on risk allele frequencies
in the population and the relative cancer risk these alleles confer50. High-penetrance alleles are
typically rare but have a strong effect (minor allele frequency (MAF) ≤0.1%, odds ratio (OR) ≥10),
whereas rare, moderate-penetrant alleles are more common with weaker effects (MAF ≤2%, OR
≥2.0), and low-penetrance alleles are even more common and have even weaker effects (MAF >10%,
OR <1.5).
Most of the common cancers are sporadic. However, approximately 5-10% of all cancers are thought
to arise due to inherited cancer syndromes caused by rare, highly penetrant germline mutations51. In
addition, approximately 10-15% of cancers are classified as “familial”, defined as a cluster of cancers
seen within a family more frequently than would be expected. These cases do not typically follow
any clear genetic inheritance pattern and their molecular background remains largely unknown.
Familial clustering of cancers is most likely due to combined effects of common low-penetrance
alleles, gene-environment interactions, or both. The clinical phenotype and cancer risk related with
different cancer predisposing alterations may also be influenced by other genetic and non-genetic
factors52.
2.5.1. Inherited cancer syndromes
Inherited cancer syndromes are usually caused by rare germline mutations that are highly penetrant,
that is, they confer high relative risks of cancer in carriers. Compared to sporadic cases, inherited
cancers are associated with distinct clinical features such as several individuals affected by the same
tumor type in the family over multiple generations, early age of onset, and individuals harboring
multiple primary cancers51. Most syndromes follow Mendelian inheritance, that is they are
monogenic and inherited in an autosomal dominant manner.
To date, germline mutations in over a hundred genes have been implicated to confer moderately or
highly increased risk of cancer52. Most of the cancer predisposition genes act as tumor suppressors
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that conform to the two-hit model of cancer susceptibility. Examples of such genes include RB1 in
retinoblastoma and APC in FAP50. Cancer predisposition genes have a broad range of functions. In
general, they are involved in fundamental cellular processes such as cell-cycle regulation and DNA
repair. BRCA2 is an example of the complexity that underlies the cancer risk conferred by cancer
predisposition genes52. BRCA2 participates in DNA repair by homologous recombination. Germline
loss-of-function mutations in BRCA2 increase the lifetime risk for breast and ovarian cancer
substantially, whereas for prostate cancer the increase is only small. The effect of BRCA2 mutations
within a particular cancer may also vary; different mutations can confer different cancer risk but also
a specific mutation may provide different risks depending on the context.
2.5.2. Other forms of genetic cancer susceptibility
The inherited cancer syndromes explain only a fraction of familial risk53. It is recognized that much
of the inherited cancer susceptibility is likely explained by polygenic inheritance. A combination of
inherited genetic changes, each with a modest individual effect, can result in a wide range of risk in
the population50. These alterations include both rare alleles with moderate penetrance and common
alleles of low penetrance. The development of genome-wide association technologies has enabled the
identification of hundreds of low-penetrant variants that confer a low risk of causing cancer53. Some
of the single nucleotide variants (SNVs) associated with elevated cancer risk are cancer-specific,
whereas others influence a variety of tumor types. In contrast to high-penetrance susceptibility
changes, low-penetrance variants might show only little to no effect on tumor phenotype50.
2.6. Next-generation sequencing
2.6.1. Sequencing efforts
The Human Genome Project, launched in 1990, was established to sequence the vast majority of the
human genome to high accuracy. A decade later, in 2001, the first drafts of the human genome were
published, followed by the first completed draft of the human genome three years later54–56. This
effort was performed by Sanger sequencing and was thus both expensive and time-consuming. The
new era of genomic analyses began when the first next generation sequencing (NGS) platform became
commercially available. Compared to the Sanger method, NGS technologies provide massively
parallel, high-throughput sequencing of short DNA fragments making it possible to sequence the
human genome within days. The dramatic reduction in costs and run time together with the improved
performance of bioinformatics tools and efficiency of data handling have enabled the generation of
large-scale genomic data.
Today, it is routine to sequence multiple exomes (protein coding regions of the genome) or genomes
simultaneously. The advances in sequencing technologies have also led to many collaborative efforts
to sequence large study cohorts. The 1000 Genomes Project was established to comprehensively
describe the common human genetic variation among multiple populations by constructing the
genomes of approximately 2,500 individuals57. The Exome Aggregation Consortium (ExAC)
collected and harmonized over 60,000 exomes from various population genetic and disease-specific
studies and created a reference set for allele frequencies in different populations58. This was followed
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by The Genome Aggregation Database (gnomAD) that includes over 125,000 exomes and over
15,000 genomes (set v2)59.
Many efforts have also been conducted towards understanding the somatic events in disease
progression, including cancer. The Cancer Genome Atlas (TCGA) has provided molecular
characterization of over 11,000 cancers and matched normal tissues including exomes from 33 tumor
types60,61. The Pan-Cancer Analysis of Whole Genomes (PCAWG) initiative has gathered genomes
of over 2,600 tumors in order to define similarities and differences between genomic mutation
patterns of various cancer types62. They detected no driver events in approximately 5% of the cancers,
implicating that the catalogue of cancer drivers is still incomplete. In a clinical setting, the MSK-
IMPACT sequencing panel was used to profile the somatic changes in over 10,000 metastatic
cancers18. As a result, 37% of the patients harbored at least one clinically actionable mutation.
The increasing amount of genomic data has provided information on various tumor predisposition
syndromes, advanced the understanding of tumor biology, and aided in identifying several disease
mechanisms. The exploration of the tumor mutation landscapes has uncovered a repertoire of driver
mutations in various cancer genes and identified mutational signatures derived from underlying
biological processes that generate somatic mutations4,63. The revolution of NGS sequencing has also
improved genetic diagnostics and provides opportunities for development of new targeted cancer
treatments18.
2.6.2. Cancer genome landscapes
The typical amount of mutations a cancer contains varies between tumor types. Common solid tumors
are estimated to display mutations in an average of 33 to 66 genes4. Childhood tumors and leukemias
contain, on average, 9.6 mutations, whereas melanomas and lung cancers harbor around 200
nonsynonymous mutations. In certain tissues where self-renewal occurs, the number of mutations is
directly correlated with age64. Tissues with more rapid cellular turnover rate, and thus with more
mitotic events, also gather more mutations. These explain partly the difference in mutation amounts
between different tumors. Pediatric cancers usually develop from non-dividing tissues and those that
do, such as leukemias, have not undergone as many mitotic divisions. Adult cancers have more
mutations, and between them, CRCs harbor a greater amount of mutations than tumors from non-
dividing tissues.
Some of the highest mutation rates are contributed by extensive exposure to well-known carcinogens,
such as smoking in lung cancer and ultraviolet radiation in melanoma. This explains variation in the
mutation amount between different cancers but also within a particular tumor type. Lung cancers of
smokers, as an example, have ten times more mutations than those of non-smokers65. In addition,
different exposures can have an impact on the distribution of mutation types. Lung cancers of smokers
have been shown to exhibit more C:G>A:T mutations, whereas non-smokers have predominantly
C:G>T:A changes. Mutation counts vary between cancer subtypes also due to key biological factors,
such as high mutation rates in CRC due to MMR deficiency or defective DNA proofreading
enzymes4,24,45,46.
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The mutation rate varies also within a cancer genome. As an example, open chromatin regions exhibit
decreased mutation density compared to gene-poor and heterochromatic regions66. This is likely due
to better accessibility of the DNA repair machinery to open chromatin areas. Regional mutational
heterogeneity exists also between protein coding regions and has been proposed to occur e.g. due to
gene expression level changes, that is, mutation rates of highly expressed genes are lower, and due to
DNA replication time, since late-replicating regions have been shown to harbor higher mutation
rates67.
The genomic landscape of many tumor types consists of a few genes that are frequently mutated, so
called “mountains”, and a large number of other genes that are mutated infrequently, termed “hills”68.
Since most of the genes are classified as hills, there is usually only little overlap between mutated
genes of two tumors even within the same histopathologic category. In addition, the majority of the
observed mutations are passenger events4. Due to variability of the background mutation rate along
the genome and between patients, methods based on mutation frequency alone cannot reliably identify
mutated driver genes. At best, they might aid in prioritizing genes for further analyses. Thus, it has
been suggested that the pattern and impact of the mutations, rather than frequency, should be
considered when estimating causality. To this end, many statistical approaches have been developed
to prioritize which genes are most likely to promote tumorigenesis when mutated69. Still,
distinguishing true driver mutations among the repertoire of somatic mutations continues to be a
major challenge.
3. Colorectal and small bowel adenocarcinoma
3.1. Background and clinical aspects
The major organs that constitute the GI tract include the stomach, the small bowel, and the
colorectum. Although it is a continuous passageway, cancer incidence varies greatly between the
different organs. The small bowel makes up approximately 75% of the length of the GI tract but only
approximately 3% of GI cancers are located in the small bowel70. Small bowel includes three
segments, duodenum, jejunum, and ileum, of which duodenum is the most common location for
adenocarcinomas71. Whereas, over 40% of GI cancers are found in the colorectum70. CRCs can be
further divided depending on their anatomical location. Proximal (or right-sided) tumors entail tumors
of the cecum, ascending colon, hepatic flexure, and two-thirds of transverse colon, whereas distal (or
left-sided) tumors include tumors of the distal third of transverse colon, hepatic flexure, descending
colon, sigmoid, and rectum72. Different molecular and histological characteristics have been
associated with these groups, such as MSI which is more commonly found in right-sided tumors.
CRC is the third most common cancer type and the second main cause of cancer deaths worldwide73.
In 2018, nearly 1.8 million new cases were diagnosed worldwide and, with estimated nearly 881,000
deaths, CRC accounted for over 9% of cancer-related deaths. Over 90% of cancers found in the
colorectum are adenocarcinomas (here referred to as CRC). The mortality rates of CRC have been
decreasing during the last two decades in many high-income countries74. This may at least partly be
due to improved screening and identification of early stage disease, as well as developments in
treatment regimens. Both genetic and environmental factors contribute to disease development.
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Predisposing syndromes include known hereditary cancer syndromes, such as FAP and Lynch
syndrome (LS, also known as hereditary non-polyposis colorectal cancer), and inflammatory bowel
disease (IBD, including Crohn’s disease and ulcerative colitis). Environmental and behavioral risk
factors include obesity, consumption of red meat and alcohol, and lack of exercise and fiber75. Studies
have indicated that use of aspirin might reduce CRC risk and improve survival76,77. These risk effects
can sometimes be challenging to determine. As an example, an individual with a predisposing
syndrome harbors a clearly increased genetic risk, whereas the contribution of germline variants to
the risk in a sporadic CRC patient may be small compared to behavioral factors.
Approximately 4% of CRC cases present more than one simultaneous lesion in the colorectum78–80.
These synchronous CRCs (SCRCs) have also been associated with the above-mentioned predisposing
syndromes that, however, are estimated to account only slightly more than 10% of SCRC cases79.
Another predisposing factor suggested as a potential causative mechanism is field effect, a process in
which a large area of cells within histologically normal-appearing tissue is affected by molecular
aberrations81,82. The proposed molecular basis for field effect includes massive exposure to a
carcinogen, genetic predisposition through mosaicism, and epigenetic changes. Compared to solitary
CRCs, some studies have associated SCRCs more often with MSI, mucinous histology, right-sided
location, presence of adenomas, and older diagnosis age83. There is no consensus on whether
prognosis differs between synchronous and solitary CRCs.
Of small bowel cancers, approximately one third are adenocarcinomas71. Other common histological
types include carcinoids, lymphomas, and sarcomas. Small bowel adenocarcinoma (SBA) is an
aggressive tumor type with an estimated five-year relative survival rate of 40%, indicating a worse
prognosis compared to that of CRC. Reasons for the rarity of SBA are not fully known. SBA and
CRC share common genetic and environmental risk factors listed above, in addition to which also
celiac disease is known to predispose to SBA84,85. Small bowel as an environment is thought to protect
more efficiently against carcinogens with fewer bacteria, shorter transit time, and the alkaline and
liquid nature of small bowel contents85. The slower stem cell division rate in the small bowel
compared to colorectum could also contribute to the difference in cancer incidence10. Regardless, the
SBA incidence has been slowly rising71. Although detection methods have improved, SBAs are still
often found at an advanced stage.
The American Joint Committee on Cancer/Union Internationale Contre le Cancer (AJCC/UICC)
TNM staging system is the standard method to classify cancers and is used as a guideline for
prognosis and treatment planning, see Table 186. This was preceded by Dukes’ classification (A-D)
which is no longer recommended for clinical use. TNM consists of three descriptive measurements
of the anatomical spreading of cancer: the extent of the primary tumor invasion (T), presence of
cancer cells in regional lymph nodes (N), and whether the tumor has metastasized into distant organs
(M). However, clinical outcomes can vary considerably among patients diagnosed with same stage
tumors. While TNM measures tumor burden at the time of diagnosis, it does not entail information
on the biological features of cancer.
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Table 1. TNM classification of CRC and SBA. Basic principles of the staging of CRC and SBA.*
T - primary tumor
T0 No evidence of primary tumor
Tis Carcinoma in situ
T1 Invades the submucosa
T2 Invades the muscularis propria
T3 Invades through the muscularis propria
T4 Invades the visceral peritoneum or adjacent organs
N - regional lymph nodes
N0 No regional lymph node metastasis
N1 1-3 positive regional lymph nodes
N2 4 or more positive regional lymph nodes
M - distant metastasis
M0 no distant metastasis
M1 distant metastasis
Stage T N M
Stage 0 Tis N0 M0
Stage I T1-T2 N0 M0
Stage II T3-T4 N0 M0
Stage III T1-T4 N1-N2 M0
Stage IV T1-T4 N0-N2 M1
*Modified from (Amin et al. 2018)
In addition to the traditional TNM classification, a method called Immunoscore® has been introduced
in literature as a possible novel way to evaluate tumor prognosis. It was developed after the amount
of immune infiltrate in CRCs were shown to correlate with better patient outcome87,88. Immunoscore
combined with TNM classification has been suggested as a new predictor of survival and therapy
response in CRC89. Its principle is based on determining the densities of CD3+ and CD8+
lymphocytes in the tumor centre and invasive margins. These data are categorized into scoring of 0-
4 (0 reflecting a low and 4 a high density of both cell types in both regions) or, as in the newest
consensus Immunoscore, from low to high.
The primary treatment for CRC, with the attempt of curative outcome, is surgical removal of the
primary cancer (and/or limited metastasis) combined with chemoradiation in certain cases90. Patients
with unresectable disease and eligible for systemic therapy can be treated with conventional
chemotherapy or newer agents, such as EGFR antibodies, antiangiogenic agents, or multi-kinase
inhibitors. Stage I and II tumors are locally invasive and can thus usually be cured by surgery. The
majority of the tumors with regional lymph node spread (stage III) are also curable with a combination
of surgery and adjuvant treatment. Tumors that have already metastasized (stage IV), however, most
often cannot be cured. SBAs have been primarily treated similarly to CRC91.
One example of molecular information translated into a clinical setting is the implementation of anti-
EGFR treatment combined with the screening of RAS mutations to indicate who will benefit from the
treatment90. New approaches in precision medicine are being investigated, such as immunotherapy
for various tumor types. PD-1 inhibitor, pembrolizumab, has been shown to be effective in MSI
tumors and the first U.S. Food and Drug Administration (FDA) approved cancer therapy towards a
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specific molecular subclass of tumors92. Tumor mutation burden in general is a proxy for the amount
of neo-antigens in the tumor cells and has become an emerging biomarker for immune checkpoint
therapy response. Also, anti-HER2 therapy has shown promise in HER2 positive metastatic CRC93.
3.2. Molecular pathogenesis
Adenocarcinomas of the colorectum and the small bowel arise from epithelial cells that are organized
as a single layer lining the intestinal wall94,95. Intestinal epithelium is rapidly renewing and shaped
into invaginations that form crypts protruding into the underlying connective tissue, and in small
bowel, also luminal protrusions that form small bowel villi. At the bottom of the crypts reside
multipotent stem cells that divide and are capable to give rise to all intestinal epithelial cell types.
Thus, all cells within a crypt are clonal and derived from the stem cells. Division of stem cells in
colorectal epithelium occurs every 24 hours giving rise to daughter cells. Stem cells of the small
bowel are thought to divide somewhat less frequently10,96. When pushed away from the bottom of the
crypts, daughter cells transform through transit-amplifying cells into mature cells, migrate up towards
the colonic intercrypt plate or the adjacent small bowel villi, and finally shed off into the intestinal
lumen.
Together with surrounding mesenchymal myofibroblasts, epithelial stem cells form a stem-cell
niche94. In a normal state, myofibroblasts produce various homeostatic signals, such as Wnt signaling
ligands, that drive epithelial cell proliferation97. The initial, gatekeeping mutation in carcinogenesis
occurs in an epithelial stem cell providing the cell growth advantage to dominate the entire crypt
through clonal expansion94,98. The mutant clones can then continue their expansion through clustering
of crypts, called aberrant crypt foci, which is the earliest detectable step. The cells migrate up the
crypt, fail to differentiate in a normal manner, and spread into the intestinal epithelium - a sequence
which leads to the formation of a tumor.
Adenocarcinomas of both small bowel and colorectum are thought to arise from an adenomatous
polyp and develop through an advanced dysplastic adenoma into an invasive adenocarcinoma99,100.
The malignant transformation results from accumulation of genetic and epigenetic alterations. The
mutation rates of some driver genes have been reported to differ in CRC and SBA85,101. The adenoma-
carcinoma sequence is a multistep process that may take up to decades to evolve into a metastatic
cancer102. During tumor evolution, the time needed for an advanced adenoma to grow into an
advanced carcinoma is suggested to be much longer than for a carcinoma to metastasize103. The most
common sites for metastatic lesions of intestinal cancers include liver, lung, and peritoneum104,105.
Despite extensive efforts, the search for driver genes specific for metastatic traits has not provided
clear results4.
A key step in the intestinal tumorigenesis is the acquisition of genomic instability43. It is considered
as an early event in tumor formation and leads to the accumulation of further genetic changes that
drive carcinogenesis towards invasive adenocarcinoma102. Tumors can acquire genomic instability in
various ways. Classically this has been divided into two distinct pathways, CIN and MSI, portrayed
in Figure 2. Additionally, a small subset of CRCs is ultramutated due to mutations in the DNA
proofreading domain of POLE or POLD145,46. These genes encode for two of the main enzymes that
replicate eukaryotic DNA. Genomic instability can also manifest through an epigenetic way.
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Although one common characteristic of CRC is global hypomethylation, a subset of CRCs exhibits
high methylation of CpG islands (including the promoter region of MLH1)106,107. These CpG island
methylator phenotype CRCs display distinct histopathological and molecular characteristics, such as
association with MSI, BRAF mutations, and serrated adenomas as the precursor108.
Figure 2. The stepwise progression of CRC. The main genetic alterations for CIN and MSI pathways are
displayed.
3.2.1. Chromosomal instability
In 1990, Fearon and Vogelstein proposed a multistep genetic model of CRC genesis, where a cell
accumulates sequential genetic changes that gives it growth advantage32. Although this theory has
been refined throughout the years, it continues serving as the basis of the carcinogenesis model and
characterizes the CIN pathway. Approximately 85% of CRCs are chromosomally unstable. Similar
frequencies have also been reported in SBA109. CIN tumors are usually microsatellite stable (MSS)
and such CRCs are often left-sided. CIN pathway consists of frequent chromosomal losses and gains,
typically including losses on chromosomal arms 5q, 17p, and 18q and gains on 8q, 13, and
20q32,100,110. CIN has been demonstrated to be an early event in tumorigenesis and to increase during
tumor progression111.
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According to the adenoma-carcinoma model, the first gatekeeping mutation happens usually in APC
located at 5q. Biallelic loss of APC initiates tumorigenesis by activating Wnt signaling pathway
leading to upregulation of oncogenic MYC112,113. Somatic inactivation of APC has been estimated to
occur in approximately 70-80% of sporadic CRCs. In APC wild-type CRCs, alternative routes to
constitutive Wnt signaling include activating Catenin Beta 1 (CTNNB1) mutations or R-spondin
fusion genes100,114. In SBA, APC mutations are thought to occur less frequently in approximately 5-
30% of tumors85,115. CTNNB1 mutations have also been reported to be relatively uncommon in SBA.
Once Wnt signaling is incessantly activated, epithelial cells of the early adenoma grow into a physical
mass that overgrows the surrounding mesenchymal tissue.
When the descendants of these cells acquire secondary advantageous changes, such as activating
mutations in KRAS, cell number increases resulting in the growth and progress of the adenoma. KRAS
mutations are typically found in adenomas larger than 1cm and in invasive adenocarcinomas100,110.
Around 40% of CRCs and 50% of SBAs harbor a KRAS mutation, typically affecting codons 12 and
13 of exon 2 and, to a lesser extent, codon 61 of exon 3100,115. These mutations result in a constitutive
activation of RAS downstream signaling and are mutually exclusive with downstream kinase BRAF
V600E mutations. BRAF mutations are found in approximately 10% of CRCs, mainly in sporadic
MSI CRC45,116,117. Up to one fifth of BRAF mutations found in CRCs are located outside the most
common mutation hotspot, V600118,119. In SBA BRAF mutations occur at a relatively same frequency
but the majority of the mutations have been proposed to constitute of atypical, non-V600
mutations115,120. Alternative mutational targets for activation of the RAF-MAPK pathway include
NRAS, EGFR, and ERBB245. Another frequently dysregulated signaling pathway is the
phosphoinositide-3-kinase (PI3K) pathway, an alternative to MAPK signaling, typically affected by
mutations in the tumor suppressor PTEN or oncogene Phosphatidylinositol-4,5-Bisphosphate 3-
Kinase Catalytic Subunit Alpha (PIK3CA). MAPK signaling route is regulated by EGFR and thus
cancers with mutated KRAS, and probably mutated BRAF, PTEN, and PIK3CA, do not respond to
anti-EGFR antibody treatment121–123.
A typically late event in carcinogenesis is the loss of tumor suppressor TP53124. In normal conditions,
p53 coordinates cellular responses to stress, including DNA damage, aberrant proliferation signals,
and oxidative stress. TP53 is mutated in 60-70% of CRCs and in approximately 40-50% of
SBAs100,115. It is usually targeted by chromosomal loss at 17p coupled with a somatic mutation in the
remaining allele125. A great majority of the somatic mutations in TP53 are missense changes100. The
transforming growth factor beta (TGFβ) signaling pathway is also frequently dysregulated45. TGFβ
signaling is usually affected by mutations in TGFBR2 and Activin A Receptor Type 2A (ACVR2A) in
MSI tumors, and in downstream mediators SMAD family members SMAD2, SMAD3, and SMAD4 in
CIN tumors.
The molecular basis for CIN is incompletely understood. It is not known whether the cause is genetic,
epigenetic, or related to abnormal architectural features of a cancer cell102. One theory behind CIN is
mutations or abnormal expression patterns of spindle-checkpoint genes, such as BUB1 and MAD2,
that regulate the mitotic spindle formation and the proper alignment and segregation of chromosomes
during mitosis102,126,127. In addition, inactivation of APC has been thought to promote CIN through its
role in maintaining chromosomal stability during mitosis128. Other factors suggested to contribute to
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CIN include telomerase dysfunction, abnormal number of centrosomes, and disruption of genes
involved in the regulation of DNA damage and replication checkpoints111.
3.2.2. Microsatellite instability
In 1993, a subset of CRCs was recognized to harbor a distinct molecular phenotype with a large
number of replication errors located frequently at the repetitive DNA tracks129–131. This, later named
MSI, is exhibited by approximately 15% of CRCs24. Of MSI CRCs, 80% arise sporadically and 20%
due to LS. In SBA, 5-35% of tumors are estimated to display MSI109.
MSI tumors arise due to a faulty DNA MMR machinery. LS patients carry a defective allele of one
of the MMR genes MLH1, MSH2, MSH6, or PMS2. Germline mutations in MLH1 and MSH2 account
for a majority of these cases100. Second inactivating hit occurs sporadically leading to MSI. MSI in
sporadic tumors is most often caused by hypermethylation of both alleles of the MLH1 promoter that
results in the loss of MLH1 expression132. MSI tumors usually have near-diploid karyotype24. They
have been associated with proximal location in colon, poor differentiation, mucinous histology,
infiltration of lymphocytes, better prognosis, low metastatic potential, and they are shown to be more
resistant to 5-fluorouracil-based adjuvant chemotherapy than MSS tumors24,133,134. Sporadic MSI
tumors also occur generally at an older age and have sessile-serrated adenoma as the precursor100,135.
DNA MMR system recognizes and orchestrates the repair of nucleotide mismatches after DNA
replication136. This system is highly conserved from bacteria to humans. The main components of this
system are MutSα (a heterodimer of MSH2 and MSH6), MutSβ (a heterodimer of MSH2 and MSH3),
and MutLα (a heterodimer of MLH1 and PMS2). Either MutSα or MutSβ detects a mismatch or an
insertion-deletion loop and creates a sliding clamp around the DNA. This is then bound by MutLα
which activates the process of repairing the mistake.
A defective MMR system results in the accumulation of mutations in the DNA, especially in areas
called microsatellites. These short repetitive stretches of DNA can be composed of mono-, di-, tri-,
or tetranucleotide repeats. They are found both in coding and non-coding regions and are prone to
expansion or shortening (i.e. instability). Insertions and deletions in microsatellites of the coding
sequence typically cause frameshifts that can lead to truncated, functionally inactive proteins. Also,
the point mutation rate is elevated24. The overall mutation rate has been estimated to be a 100-fold
higher in MSI compared to MSS cancers45,137. Ultimately, clones that acquire mutations in key driver
genes due to faulty MMR, gain growth advantage that promotes tumorigenesis26.
Since a majority of the mutations in MSI cancers are passenger events, it has been challenging to
distinguish drivers that contribute to tumorigenesis. Many criteria have been proposed for defining
true MSI target genes, such as high frequency of biallelic inactivating changes, association to a growth
suppressive pathway, the same pathway inactivated in MSS tumors, and functional evidence138. Many
candidate MSI target genes have been reported, however, only few genes have robust functional
evidence. These well-established MSI target genes include TGFBR2 and ACVR2A139,140.
Additionally, only a few oncogenic changes have been confirmed to have a role in MSI
carcinogenesis. The best characterized is a hotspot mutation BRAF V600E, occurring in over 40% of
sporadic MSI CRCs26,45. Other genes harboring causative point mutation hotspots include KRAS,
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CTNNB1, and PIK3CA100. Compared to MSS CRC, APC, KRAS, and TP53 generally exhibit less
frequent mutations in MSI tumors45,141.
The standard method of detecting MSI is the polymerase chain reaction (PCR)-based Bethesda panel
that consists of five markers: two mononucleotide repeats (BAT25 and BAT26) and three
dinucleotide repeats (D5S346, D2S123, and D17S250)142. According to the guidelines, a sample is
considered MSI-high when two or more markers show instability138. If only one marker is mutated,
the tumor is referred to as MSI-low. Discontinuation of this category has been proposed, however,
since MSI-low tumors display biological similarities with MSS tumors143. Another approach is to
perform immunohistochemical (IHC) staining on the MMR proteins. A tumor is diagnosed with
MMR deficiency if expression of one or more of these proteins is abnormal. This method is often
utilized in the clinical setting and its sensitivity and specificity corresponds to that of the Bethesda
panel24. MMR genes with abnormal expression may be sequenced to further determine the causative
change. Additionally, NGS has provided opportunities to detect MSI status from large-scale
sequencing data with high accuracy144. This has led to the development of multiple NGS-based MSI
classifiers145–147. However, no consensus on the calling parameters have thus far been determined.
Also, normal tissue contamination in DNA-based testing or interpretation of antibody-based tests can
sometimes create challenges for obtaining accurate results.
3.2.3. Advances in characterizing the genetic landscape
In recent years, large-scale NGS efforts have been conducted to improve our understanding of the
CRC mutation landscape. Knowledge on the general amount and distribution of mutations has
revealed CRCs to harbor only a handful of commonly mutated genes68. Each tumor contains a unique
set of mutations of which the majority are passengers. Hence, statistical methods have been developed
to evaluate the significance of mutations and this has led to the discovery of new driver genes
associated with various biological processes45,68,148. Examples of novel driver genes include ARID1A,
involved in chromatin remodeling, and POLE, where somatic mutations in the proofreading domain
cause the ultramutated phenotype found in approximately 1% of CRCs45. Also novel non-coding
mutational patterns have been discovered in CRC149,150.
Large-scale sequencing data has also enabled the detection of mutational signatures45,63. Different
mutational processes, such as mistakes occurring during DNA replication or mutagen exposures,
generate unique combinations of mutation types, referred to as mutational signatures. Mutational
signatures (and their proposed etiology) found in CRC include 1A (aging), 6 (MSI), 10 (POLE
mutations), and 17 (cause unknown)63,149. CRCs have also been classified into four distinct groups by
gene expression studies151. These consensus molecular subtypes are CMS1 (MSI immune), CMS2
(canonical), CMS3 (metabolic), and CMS4 (mesenchymal).
Such large-scale studies have not been conducted on SBA. Therefore, less is known about the
mutation landscape specific to this tumor type. Studies have mainly focused on known mutational
hotspots or a set of known cancer genes115,120,152. There have been a few exome-wide studies on a
limited number of duodenal tumors153,154. These have shown that the most frequently affected genes
include similar driver genes as in CRC, such as TP53, KRAS, SMAD4, and APC85,115. DNA copy
number changes in SBA might be more similar to those observed in CRC than in gastric cancer155.
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3.3. Hereditary predisposition
Approximately one-third of all CRCs are thought to arise due to familial predisposition156. Mendelian
cancer syndromes resulting from a high penetrance germline mutation have been estimated to account
for approximately one fifth of these cases157. The majority of SBAs are also assumed sporadic101. The
most common hereditary syndromes predisposing to CRC and SBA are LS and FAP (Table 2.)101,157.
The next most common syndromes include MUTYH-associated polyposis (MAP), juvenile polyposis
syndrome (JPS), and Peutz-Jeghers syndrome (PJS). LS, FAP, and MAP are characterized by the
development of adenomatous polyps, whereas in JPS and PJS the primary lesions are hamartomatous
polyps.
Table 2. Summary of the most common hereditary syndromes for CRC and SBA.
Syndrome Gene(s) Gene Function Inheritance
LS MLH1, MSH2, MSH6, PMS2 DNA mismatch repair autosomal dominant
FAP APC Wnt signalling autosomal dominant
MAP MUTYH DNA base excision repair autosomal recessive
JPS SMAD4, BMPR1A TGFβ signalling autosomal dominant
PJS STK11 Activation of AMPK-related kinases autosomal dominant
Other rarer syndromes predisposing to CRC also exist, such as serrated polyposis and polymerase
proofreading–associated polyposis. Serrated polyposis is characterized by several serrated polyps in
the colon and, on average, a five-fold increased risk for CRC158. Genetic background of the disease
remains largely unknown. Polymerase proofreading-associated polyposis is an autosomal dominant
disease caused by germline mutations in the exonuclease domains of POLE and POLD146. This leads
to hypermutated tumors characterized mainly by increased rate of base substitutions. Patients seem
to exhibit variable phenotypes that include several colorectal adenomas and carcinomas159.
Much of the heritable risk for CRC remains molecularly unexplained. It is thought to derive from
alleles with lower penetrance, some of which have been identified160. One well-established moderate-
penetrance variant is APC I1307K that is found in ~6% of Ashkenazi Jews and increases the risk for
CRC two-fold161. Genome-wide association studies have identified many loci with low-penetrance
alleles associated with CRC162–165. One of the most interesting regions found in these studies is located
at 8q24, with the polymorphism rs6983267166. Later studies have identified a cancer-specific
enhancer element at this region that has been proposed to control the expression of MYC
oncogene167,168. In general, the distinction between familial (excluding the cases due to a well-known
predisposing variant) and sporadic CRCs can be difficult since a large number of predisposition
alleles with varying risk levels and prevalence in the population are likely to collectively contribute
to the genetic susceptibility to CRC in both cases160.
3.3.1. Lynch syndrome
LS, the most common genetic predisposition syndrome for CRC and SBA, accounts for
approximately 5% of the cases in both tumor types101,160. Among mutation carriers, lifetime risk for
developing MSI SBA is 2-8% and MSI CRC 39–70%85. LS is inherited in an autosomal dominant
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manner and predisposes to various types of MSI tumors, especially colon and endometrial51,169. Other
cancers seen in LS include stomach, small bowel, ovary, hepatobiliary system, and upper urinary
tract. Patients with LS display also more synchronous and metachronous MSI CRCs. Compared to
sporadic cases, LS-associated CRCs are usually diagnosed at an earlier age, with the average age of
onset approximately 45 years, and have a better prognosis51,170. LS-associated tumors rarely harbor
somatic BRAF V600E mutation which is found in approximately 40% of sporadic MSI CRCs116,171.
In 1993, a linkage to 2p15-16 was observed in many LS families providing the first susceptibility
locus for the syndrome 172. Subsequently, MSH2 was identified as the predisposing gene173,174. At the
same time, LS tumors were shown to display variation in microsatellite lengths, linking the syndrome
to defective MMR129. This was followed by the discovery of MLH1 germline mutations at 3p21175–
177. Later, germline mutations in two other key MMR genes, MSH6 and PMS2, and deletion of the 3’
end of EPCAM have also been linked to LS178–181. Together, MLH1 and MSH2 germline mutations
explain approximately 90% of LS cases182. In Finland, two founder mutations in MLH1 account for
approximately 60% of inherited LS mutations183.
Several international diagnostic criteria have been introduced for identifying LS patients. These
include Amsterdam criteria I & II and the Bethesda guidelines, see Table 3142,184–186. Since there are
no clinically distinct features associated with LS, the diagnosis is confirmed only by a gene test.
Furthermore, since the clinical criteria are not sensitive enough to catch all LS cases and MSI status
affects prognosis and possibly the adjuvant treatment, many international clinical guidelines
recommend MSI screening of all newly diagnosed CRC cases187. For mutation carriers, surveillance
colonoscopy is recommended every 1-3 years from the age 20-25 onwards188–190. The surveillance
recommendations for LS-associated extracolonic cancers vary.
Table 3. Diagnostic criteria for identification of LS patients and the guidelines for testing colorectal
tumors for MSI.
The revised ICG-HNPCC Criteria (Amsterdam criteria II) *
There should be at least 3 relatives with an LS-associated cancer (CRC, cancer of the endometrium, small bowel,
ureter, or renal pelvis)
One should be a first-degree relative of the other 2
At least 2 successive generations should be affected
At least 1 should be diagnosed before age 50
Familial adenomatous polyposis should be excluded in the CRC case(s) if any
Tumors should be verified by pathological examination
The revised Bethesda guidelines **
Tumors from individuals should be tested for MSI in the following situations:
1) CRC diagnosed in a patient who is less than 50 years of age
2) Presence of synchronous, metachronous colorectal, or other HNPCC associated tumors, regardless of age.
3) CRC with the MSI histology (Presence of tumor infiltrating lymphocytes, Crohn’s-like lymphocytic reaction,
mucinous/signet-ring differentiation, or medullary growth pattern) diagnosed in a patient who is less than 60 years
of age.
4) CRC diagnosed in one or more first-degree relatives with an HNPCC-related tumor, with one of the cancers being
diagnosed under age 50 years.
5) CRC diagnosed in two or more first- or second-degree relatives with HNPCC-related tumors, regardless of age.
*Reprinted from Gastroenterology 116/6, Vasen et al. New clinical criteria for hereditary nonpolyposis colorectal
cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC, p.1455, Copyright
(1999), with permission from Elsevier; **Umar et al. Revised Bethesda Guidelines for hereditary nonpolyposis
colorectal cancer (Lynch syndrome) and microsatellite instability, J Natl Cancer Inst. 2004, 96/4, p.15, by
permission of Oxford University Press.
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3.3.2. Familial adenomatous polyposis
Approximately 0.5% of CRCs are due to FAP, making it the second most common inherited CRC
syndrome191. In SBA, FAP is estimated to be present in less than 5% of cases101. FAP is characterized
by hundreds to thousands of adenomas in the colorectum, typically beginning to develop during
adolescence. In case prophylactic surgery is not performed, CRC will develop in nearly all affected
individuals by the age of 50157. Extracolonic manifestations include hypertrophy of retinal pigment
epithelium, gastric fundic gland polyps, and duodenal adenomas51. FAP patients have also an
increased risk for extracolonic malignancies. Of these, duodenal cancer is the most common with a
lifetime risk up to 10%190. After the removal of CRC risk by total colectomy, duodenal cancer remains
as one of the main causes for mortality192.
This autosomal dominant condition is caused by inactivating germline mutations in APC. Protein
truncating mutations make up over 95% of the inherited mutations160. Up to 25% of FAP patients,
however, have a negative family history and present a de novo germline mutation in APC193. A clinical
diagnosis of FAP can be made when over a hundred colorectal adenomas are detected51. A gene test
is recommended to confirm the diagnosis. Genetic testing is also recommended for individuals with
10-20 colorectal adenomas, typical extraintestinal manifestations, or if there is a known APC mutation
in the family. Annual endoscopy surveillance should be offered for all mutation carriers190. The
primary prophylactic measure for FAP is colectomy or proctocolectomy.
Attenuated FAP is a less severe form of the disease in which the amount of polyps varies between 10
and 100 and has on average a later age of onset194. Another variation of FAP is called Gardner
syndrome, where in addition to FAP, patients can present desmoid tumors, epidermoid cysts,
osteomas, and dental anomalies51.
3.3.3. Other syndromes
MAP is caused by biallelic mutations in the gene MUTYH and is inherited in an autosomal recessive
manner195. MUTYH is a base-excision repair gene and when impaired, tumors gather an excess
amount of G:C>T:A transversions. The disease manifests usually by the time patients reach their
sixties196. The clinical phenotype resembles that of attenuated FAP and thus genetic testing of
MUTYH is warranted in patients with more than ten adenomas and no detectable APC mutation157.
Unlike in attenuated FAP, however, MAP patients present hyperplastic polyps in addition to
adenomatous polyps. The risk for duodenal cancers is slightly elevated197.
PJS is an autosomal dominant syndrome characterized by hamartomatous polyps along the GI tract,
located most often in the small bowel157. PJS predisposition has been linked to germline mutations in
STK11 (also known as LKB1) that encodes for a serine/threonine kinase198. The syndrome has almost
complete penetrance. GI symptoms, such as obstruction and bleeding, usually occur already during
early teens157. The most typical extracolonic manifestation is mucocutaneous pigmentation. Mutation
carriers have an increased risk for multiple malignancies, such as female breast, colon, pancreas,
stomach, ovary, lung, and small bowel cancers199. Although PJS polyps occur most frequently in the
small bowel, the most common site for GI cancer is the colon.
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JPS is also a hamartomatous polyposis syndrome with autosomal dominant inheritance and almost
complete penetrance157. Germline mutations in TGFβ signaling pathway genes SMAD4 or BMPR1A
are known to predispose to JPS200,201. Unlike PJS, JPS does not typically have clinical manifestations
to facilitate diagnosis157. Juvenile polyps are most commonly found in the colorectum but also in the
small bowel and the stomach. Mutation carriers harbor an increased risk for CRC, gastric, small
bowel, and pancreatic cancer. Congenital defects are present in approximately 15% of JPS patients.
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AIMS OF THE STUDY
The main aim of this thesis work was to provide further insight into the genetic background of CRC
and SBA utilizing exome sequencing. The specific aims are listed below.
I. To study the mutation pattern of ARID gene family in MSI CRC
II. To identify novel oncogenes with somatic mutation hotspots in MSI CRC
III. To examine the genetic overlap within synchronous CRC pairs
IV. To characterize the somatic mutational landscape of SBA
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MATERIALS AND METHODS
The materials and methods used in this thesis work are presented briefly below. More detailed
descriptions can be found in the original publications (referred to by their Roman numerals).
1. Ethical approval
The studies were conducted according to the Declaration of Helsinki and approved by the Ethics
Committee of the Hospital District of Helsinki and Uusimaa, Finland (408/13/03/03/2009). Either a
signed informed consent or authorization from the National Supervisory for Welfare and Health was
obtained for all the samples, as determined in the National legislation.
2. Sample material
2.1. Microsatellite unstable colorectal cancers (I-II)
The discovery set of 25 sporadic MSI CRCs and their corresponding normal samples for studies I-II
was derived from a population-based series of 1,042 Finnish CRCs collected 1994-1998 (the C
series)202,203. Collection was continued with a subsequent, ongoing cohort of Finnish CRCs (the S
series) collected in two Finnish central hospitals since 1998204. These collections consist of fresh-
frozen tumors and their corresponding fresh-frozen healthy colorectal tissue samples or blood. Tumor
samples have been examined for MSI by radioactive labeling techniques, fluorescence-based PCR,
or fragment analysis202–204. Detailed clinicopathological information was available for all patients.
In study I, an independent validation set consisting of 21 sporadic MSI CRCs was obtained from the
two above-mentioned cohorts. In study II, the independent validation set was composed of 167
Finnish MSI CRCs (42 LS and 125 sporadic cases) from the two above-mentioned cohorts and 87
Danish MSI CRCs. Corresponding normal samples were available for somatic validation of the
findings.
2.2. Synchronous colorectal cancers (III)
The sample set in study III consisted of 23 SCRC pairs and their corresponding normal tissue samples.
Of these, 20 patients were obtained from a population-based series of 1,088 CRCs from Jyväskylä,
Finland and three patients from the above-mentioned C and S series. We included all patients with
available tumor material from the paired CRC tumors. The set included 59 formalin-fixed paraffin-
embedded (FFPE) samples and 11 fresh-frozen samples. From one patient we had three tumors to
study and this patient belonged to a LS family. Other cases were assumed sporadic. All relevant
clinicopathological information was available. For Jyväskylä samples, MMR status was determined
by IHC staining.
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2.3. Small bowel adenocarcinomas (IV)
We obtained information on all patients diagnosed with SBA in Finland during years 2003-2011 from
the Finnish Cancer registry. Cases reported without histopathological confirmation of small bowel
primary tumor or only by autopsy were excluded. Also, tumors of the papillary region were excluded
as these may have derived from the pancreas or the biliary tract. We examined the FFPE tissue blocks
of the remaining 162 patients and selected all cases with available tumor material and a minimum of
50% tumor content. Of these, one case was later omitted due to low sequencing depth. Thus, the final
set was composed of 106/162 (65%) confirmed SBA cases (excluding autopsies). The set included
tumors from all three segments of the small bowel (26 duodenal, 52 jejunal, and 18 ileal tumors)
together with ten tumors without a specified location. Six patients had a hereditary syndrome (four
LS and two FAP), the rest were assumed sporadic. All relevant medical records for the cases were
available for the study.
2.4. Cell lines (II)
Genomic DNA from ten CRC cell lines (VACO5, CCL231, GP5D, HCA7, HCT-116, LOVO,
LS174T, RKO, SNUC2B, and DLD1) were utilized for further validation of mutation hotspots. The
cell lines were obtained from the American Type Culture Collection, the European Collection of Cell
Culture, or provided by Professor Ian Tomlinson.
3. Genetic analyses
3.1. DNA extraction (I-IV)
The extraction of genomic DNA for fresh-frozen tissue was done with a non-enzymatic DNA
extraction protocol (I-III), and for FFPE blocks with a standard phenol-chloroform isolation method
(III-IV) or GeneRead FFPE-kit (QIAGEN, Hilden, Germany) (IV).
3.2. Exome sequencing (I-IV)
Genomic libraries were prepared with NEBNext DNA Sample Prep Reagent Set 1 Kit (New England
Biolabs, Ipswich, MA, USA) (I-II) or KAPA Hyper Prep Kit (Kapa Biosystems, Wilmington, MA,
USA) (III-IV). Exomic regions were enriched with the Agilent SureSelect All Exon Kit v1 (Agilent,
Santa Clara, CA) (I-II) or the NimbleGen SeqCap EZ Exome Library v3 Kit (Roche NimbleGen,
Madison, WI, USA) (III-IV). For I-II, paired-end short read sequencing was performed with Illumina
Genome Analyzer II (Illumina, San Diego, CA, USA) at the Karolinska Institute, Sweden or the
Finnish Institute for Molecular Medicine (FIMM) Genome and Technology Center, Finland. For III
and IV, the paired-end sequencing was carried out with Illumina HiSeq 2000 or 4000 (Illumina) at
the Karolinska Institute.
The raw sequencing data was run through an in-house analysis pipeline constructed for exome
sequencing data. This included the following tools and programs: FastQC
(http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc/) (I-IV), QualiMap205 (III-IV), Trim Galore!
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(http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/) (III-IV), Burrows-Wheeler
Aligner206 (I-IV), BamUtil ClipOverlap (http://genome.sph.umich.edu/wiki/BamUtil#Releases) (III-
IV), Picard Tools MarkDuplicate (http://picard.sourceforge.net) (I-II) or Samtools rmdup (III-IV)207,
the Genome Analysis ToolKit (GATK) IndelRealigner208 (I-IV), GATK BaseRecalibrator (I-IV),
Samtools mpileup (I-II)207, and the GATK UnifiedGenotyper (I-II) or GATK HaplotypeCaller (III-
IV). Instead of Trim Galore!, an in-house script was used in studies I-II to remove 3’ read ends with
high adapter similarity. Samtools rmdup was used to remove duplicate reads on both paired-end and
single-end reads to correct for e.g. FFPE-derived sequencing artefacts. The version GRCh37/Hg19
was used as the human reference sequence.
In studies I-III, somatic mutations were extracted by filtering the tumor exome data against the exome
data from the corresponding normal tissues. The remaining variant calls were refined by filtering
them either against 93 Finnish samples from the 1000 Genomes Project (www.1000genomes.org/),
single nucleotide polymorphisms (SNPs) available at the dbSNP database (Build 132;
www.ncbi.nml.nih.gov/SNP/), and 69 population matched exomes from other projects in the
laboratory (I-II) or a pooled set of whole-genome sequencing data from ten blood samples (III). For
study III, germline mutations were obtained by filtering the normal tissue exome data against the
whole gnomAD (http://gnomad.broadinstitute.org/). Germline mutations were excluded if they were
present with a MAF >0.001 in the whole gnomAD or in the Finnish gnomAD exomes, or >0.01 in
the Finnish genome set. In study IV, somatic mutations were called from the tumor exome data using
similar methods to those reported in Hiltemann et al.209 together with additional filtering steps and
larger population and sequencing pipeline specific datasets (in-house whole genome sequenced
(WGS) normal samples (n = 183), a pooled set of ten blood sample genomes, and gnomAD set of
exome and WGS normal samples (n = 138,632)). BasePlayer (earlier version called RikuRator) was
used to visualize and analyze the exome data (I-IV)210. The specific criteria to call a mutation varied
between studies: GATK quality score at least 20 (I, III) or 50 (II), minimum total coverage 4 (III) or
5 (I-II), and the minimum mutant allele fraction 10% (III) or 20% (I-II). For study IV, recommended
GATK hard filters were used (see Supplementary Table S8 in the original publication). Filtering steps,
including mapping quality, were used to filter out false calls that derive e.g. from FFPE material. In
addition, 1000 Genomes phase 1 pilot-style callability region mask was used to filter out possible
false calls, such as deamination artefacts due to FFPE, located in regions with poor callability (III).
3.3. Sanger sequencing (I-IV)
Sequencing primers were designed with ExonPrimer (http://ihg.gsf.de/ihg/ExonPrimer.html) (I-II)
and Primer3Plus (I-IV)211. For FFPE samples, PCR reactions were performed in triplicates to ensure
consistency of the observations. Sequencing reactions were performed with the Big Dye Terminator
v.3.1 kit (Applied Biosystems, Foster City, CA, USA) on an ABI3730 Automatic DNA Sequencer
(FIMM Technology Center and DNA sequencing and Genomics laboratory, Institute of
Biotechnology, Helsinki, Finland). The sequence graphs were analyzed both with the Mutation
Surveyor software (Softgenetics, State College, PA) and manually.
Sanger sequencing of genomic DNA was used for validation of selected findings, screening of
additional tumors, and verification of the somatic nature of these findings (I-IV). To study the
expression of ANTXR Cell Adhesion Molecule 1 (ANTXR1) mutant alleles, cDNA sequencing was
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applied to seven ANTXR1 mutated tumors from which RNA isolated from fresh-frozen tumor tissue
was available (II).
4. Computational methods
4.1. In silico mutation effect prediction (I-II)
Ensembl Variant Effect Predictor (VEP) that includes SIFT (http://sift.jcvi.org/) and PolyPhen-2
(http://genetics.bwh.harvard.edu/pph2/) was ran to predict the functional consequences of the
mutations (I-II). ClustalW2 (http://www.ebi.ac.uk/Tools/msa/clustalw2/) was used to perform
multispecies protein sequence alignments (II).
4.2. Statistical analyses (III-IV)
R was used to perform statistical analyses in studies III (v.3.5.1) and IV (v.3.4.1) (R Foundation for
Statistical Computing, Vienna, Austria; https://www.R-project.org/). In study III, Spearman’s rank
correlation coefficient was applied to evaluate the correlation of IS within tumor pairs and generalized
estimating equations (GEE) with ordinal response were used to examine the association between IS
and clinicopathological variables212. For study IV, Fisher’s exact test was used to test for
independence of the categorical variables. For continuous variables, Mann-Whitney U test was
applied. Cox proportional hazards regression with Firth's penalized likelihood was used to analyze
the disease-specific survival. This model included MMR status, sex, tumor stage, and age at diagnosis
as covariates. Negative binomial regression was used to estimate per-tumor mutation counts
attributable to mutational signatures in MSS tumors and whether they associate to any clinical
variables. P-values were two-sided, unadjusted for multiple comparison, and P <0.05 was regarded
as statistically significant.
4.3. Mutation signature analysis (III-IV)
In study III, an in-house method was applied to detect mutational signatures from the exome data.
Mixed linear model was used to compare the variation of signature contents between tumors.  A
detailed description of these models can be found in the original publication. Comparison of the
modeled signatures to the published signatures was performed using Maximum-A-Posteriori
probability signatures63.
In study IV, using all mutations within exome target regions, mutation signature analysis was
performed by non-negative matrix factorization of six substitution types. The obtained signatures
were compared to the published signatures213. Fifteen tumors displayed MSI signature (signature 6).
These MSI tumors were grouped separately and the mutation signature analysis was subsequently
performed for the 91 MSS samples.
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4.4. Ingenuity Pathway Analysis (III-IV)
Ingenuity Pathway Analysis (IPA) was used to determine the frequency of which known cancer
pathways (ATM, p53, Wnt/β-catenin, ERBB, PTEN, PI3K/AKT, MAPK/ERK, and TGFβ) were
affected within tumor pairs (III) and in MSS SBAs (IV). We used this program to define genes linked
to these pathways. The analysis considered all genes with at least one non-synonymous mutation.
4.5. OncodriveFML (IV)
OncodriveFML was utilized to identify genes displaying statistical evidence of positive selection for
mutations in the 91 MSS SBAs. This permutation-based method used the somatic mutations within
the coding area and compared the region’s mean functional impact score to its null distribution by
randomizing observed mutations within the coding sequence. Default settings were used. The
performed analysis focused on genes mutated in at least four tumors.
4.6. Allelic imbalance analysis (IV)
In study IV, allelic imbalance (AI) regions were called in the 106 tumors using SNVs that filled the
following criteria: rs-coded, minimum of 10 coverage at the variant call locus, not defined as somatic
in the study, location within exome target region, and did not overlap with regions prone to false AI
calls. The AI regions were called with B allele frequency segmentation algorithm214.
5. Immune cell score determination
In study III, the immune cell score (IS) was determined using the same basic principles as in
Immunoscore®88. The IS consists of CD3 and CD8 lymphocyte counts from tumor centre and
invasive margin. CD3 (Novocastra, NCL-L-CD3, clone PS1) and CD8 (Thermo Scientific, RM-9116,
clone SP16) antibodies were used for IHC staining of whole tissue sections. Slides of the tissue
sections were then digitally scanned with NanoZoomer-XR (Hamamatsu Photonics K.K., Hamamatsu
City, Japan) and QuPath image analysis software was used to calculate the amount of positively




1. Mutation profiles of ARID genes in MSI CRC (I)
1.1. Screening of the 15 ARID domain containing genes
We studied the somatic mutation pattern of all 15 ARID domain containing genes in 25 MSI CRCs.
The following 12 ARID genes harbored at least one mutation: ARID1A, ARID1B, ARID2, ARID3A,
ARID4A, ARID4B, ARID5A, JARID2, KDM5A, KDM5B, KDM5C, and KDM5D. Their mutation
frequency varied between 4-52% (1-13 mutations in the 25 tumors). No mutations were found in
ARID3B, ARID3C, or ARID5B. Twenty out of the 25 tumors (80%) presented at least one
nonsynonymous mutation in one of the 12 mutated genes.
1.2. Four ARID genes frequently mutated
Four genes, ARID1A, ARID1B, ARID2, and ARID4A, were chosen for further analysis since they
fulfilled the criteria of being mutated in at least four tumors and included at least one splice-site or
nonsense mutation. Mutations encountered in these four genes in exome data were validated and their
somatic origin was confirmed by Sanger sequencing. Furthermore, the coding regions of these genes
were screened with Sanger sequencing in an additional set of 21 MSI CRCs.
For all four genes the relatively high frequency of nonsynonymous mutations was confirmed. We
observed 6-18 nonsynonymous mutations per gene in the 46 tumors (13-39%), see Figure 3. A
majority of the tumors (28/46, 61%) harbored a nonsynonymous mutation in at least one of the four
genes, and nine tumors contained mutations in two or more of the four genes. The mutation spectrum
included 47 different mutations: 18 frameshift (38%), 18 missense (38%), seven synonymous (15%),
three nonsense (6%), and one splice-site (2%) mutations. Besides a mutation cluster in a known
mutation hotspot of a mononucleotide repeat in ARID1A, p.D1850fs, mutations were scattered along
the genes.
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Figure 3. Mutations in ARID1A, ARID1B, ARID2, and ARID4A. Distribution of somatic, non-synonymous
mutations detected by sequencing in the coding regions of these genes are presented. Each dot represents one
mutation. Only some domains are displayed for clarity. Copyright (2014) Wiley. Reproduced with permission
from Cajuso et al, 2014, IJC, Wiley.
ARID1A, the most frequently mutated of the four genes, harbored a nonsynonymous mutation in 18
out of 46 tumors (39%). Seven of these tumors contained two ARID1A mutations. Altogether 19
different mutations were observed. The majority of these were frameshift mutations (12/19, 63%).
The above-mentioned known hotspot mutation (p.D1850fs) was identified in seven tumors. Four of
these mutations were observed only when visualizing exome data of each sample individually to
detect all possible mutations at this locus. There were also one splice-site and six missense mutations.
Three of the missense mutations were predicted to be damaging by Ensembl Variant Effect Predictor.
ARID4A was the second most frequently mutated gene with altogether ten mutations in nine tumors
(9/46, 20%). Half of these mutations were missense changes, all of which were predicted to be
damaging. In addition, we observed one nonsense and three frameshift mutations.
ARID1B mutations were encountered in six tumors (6/46, 13%). These mutations included four
missense, one nonsense, and one frameshift change. Three of the four missense mutations were
predicted to be damaging. Three tumors harbored a concurrent ARID1A and ARID1B mutation.
ARID2 was mutated also in six tumors. Here, the mutation spectrum consisted of three missense, one
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nonsense, and two frameshift mutations. Two out of the three missense mutations were predicted as
damaging.
Finally, we studied whether mutations in these four ARID-encoding genes co-occurred with
mutations in known cancer genes KRAS, BRAF, or TP53. Twenty out of 46 tumors (43%) harbored a
BRAF V600E mutation, two (4.3%) contained a mutation in KRAS exon 2 and nine (20%) in TP53
exons 5-8, Figure 4. There seemed to be no clear correlation between the mutations in any of the four
ARID genes and KRAS, BRAF, or TP53. This could, however, be due to the relatively small sample
set.
Figure 4. Nonsynonymous somatic mutations detected in the four candidate ARID genes, KRAS (exon
2), BRAF (V600E), and TP53 (exons 5-8). Each column represents one tumor and each row a gene. No
exclusivity between any of the ARID genes and KRAS, BRAF, or TP53 was observed. Copyright (2014) Wiley.
Reproduced with permission from Cajuso et al, 2014, IJC, Wiley.
2. Novel candidate oncogenes in MSI CRC (II)
2.1. Discovery of potential oncogenes with a mutation hotspot
We searched for novel oncogenes systematically in a set of 25 exome sequenced sporadic MSI CRCs.
Our effort focused on identifying recurrent missense mutations hitting the exact same base in at least
two tumors. Other than identical base-specific hotspot mutations had been investigated in this set by
a previous study217. Our search resulted in a list of 42 genes that had possible heterozygous somatic
hotspot mutations. Of these, 36 were confirmed real and somatic by Sanger sequencing. This included
three known oncogenes PIK3CA, CTNNB1, and BRAF together with 33 candidate driver genes.
2.2. Fourteen genes harbor additional hotspot mutations
The 33 recurrent somatic missense mutations were then screened by Sanger sequencing in a validation
set of 254 MSI CRCs. The following 14 candidate genes displayed additional hotspot mutations:
ANTXR1, CEP135, CRYBB1, MORC2, SLC36A1, GALNT9, PI15, KRT82, CNTF, GLDC, MBTPS1,
OR9Q2, R3HDM1, and TTPAL (Table 4). Here, all mutations residing in the same codon as the
mutation in the discovery set were considered as a hotspot mutation. Altogether 28 (11%) tumors in
the validation set, and 40 (14%) tumors in both sets combined, harbored at least one of the novel
hotspot mutations. The most prominent gene was ANTXR1, harboring a hotspot mutation R438C
altogether in seven (2.8%) validation set MSI CRCs. This hotspot was located in the anthrax-binding
41
domain. However, no expression of the mutant allele of ANTRX1 was detected in the five tumors
available for the analysis. The mutation pattern of ANTXR1 is displayed in Figure 5. The next frequent
hotspots in the validation set were CEP135 R1115C and CRYBB1 A171T, both mutated in 1.2% of
the samples. The hotspot mutation pattern in MORC Family CW-Type Zinc Finger 2 (MORC2) varied
somewhat compared to other genes. In addition to harboring one discovery hotspot mutation (S25L)
in the validation set, MORC2 contained another hotspot nearby, found in one discovery set and one
validation set tumor (K27R/M). Known hotspots in oncogenes BRAF, KRAS, PIK3CA, and CTNNB1
were also screened and they displayed mutations in the validation set with the following frequencies:
42%, 15%, 5.5-11%, and 6.9%, respectively.
Table 4. Fourteen novel candidate oncogenes with validated somatic hotspots. Adapted from Tuupanen et









ANTXR1 ANTXR Cell Adhesion Molecule 1 R438C 3 (12%) 7/251 (2.8%)
CEP135 Centrosomal Protein 135 R1115C 2 (8%) 3/245 (1.2%)
CRYBB1 Crystallin Beta B1 A171T 2 (8%) 3/248 (1.2%)
MORC2 MORC Family CW-Type Zinc Finger 2 S25L / K27M 3* (12%) 2**/244 (0.8%)
SLC36A1 Solute Carrier Family 36 Member 1 A136T 3 (12%) 2/253 (0.8%)
GALNT9 Polypeptide N-Acetylgalactosaminyltransferase 9 R8C 2*** (8%) 2/238 (0.8%)
PI15 Peptidase Inhibitor 15 A105V 2**** (8%) 2/247 (0.8%)
KRT82 Keratin 82 R496W 2 (8%) 1/252 (0.4%)
CNTF Ciliary Neurotrophic Factor T35M 2 (8%) 1/251 (0.4%)
GLDC Glycine Decarboxylase R962Q 2 (8%) 1/249 (0.4%)
MBTPS1 Membrane Bound Transcription Factor Peptidase, Site 1 A368T 2 (8%) 1/253 (0.4%)
OR9Q2 Olfactory Receptor Family 9 Subfamily Q Member 2 A249T 2 (8%) 1/251 (0.4%)
R3HDM1 R3H Domain Containing 1 R296Q 2 (8%) 1/251 (0.4%)
TTPAL Alpha Tocopherol Transfer Protein Like R147C 2 (8%) 1/252 (0.4%)
*2x S25L, 1x K27M; **1x K27R, 1x S25L; ***1x R8S, 1x R8H; ****1x A105T, 1x A105V
Figure 5. The spectrum of validated ANTRX1 mutations. The hotspot mutation (R438C) was discovered
altogether in ten tumors (three in discovery set and seven in validation set). The other validated mutations
observed in this study were R250H and P430L (in MSS CRCs) and R480C (discovery set MSI CRC). rcpt =
receptor. Reproduced from Tuupanen et al. (2014), BJC, Springer Nature under the Creative Commons
Attribution-NonCommercial-Share Alike 3.0 Unported License.
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In most of the genes (10/14, 71%), the targeted hotspot amino acids showed high conservation in
multispecies protein alignments. These genes were ANTXR1, MORC2, CEP135, GALNT9, PI15,
KRT82, GLDC, MBTPS1, R3HDM1 and TTPAL. The amino acid substitutions in these ten genes
together with SLC36A1 were also predicted to have a damaging or deleterious effect.
Next, the 14 validated novel hotspots were examined in in-house data of ten CRC cell lines and 91
WGS MSS CRCs. In the cell lines, two mutations were found: MORC2 S25A in HCA7 and OR9Q2
A249T in DLD1. In MSS CRCs, no hotspot mutations were detected. However, ten of the 14 genes
harbored other coding mutations (see Supplementary Table S4 in the original publication). One of
them was ANTXR1 with two missense mutations (R250H and P430L), Figure 5. Since ANTXR1 was
our most prominent hit, these two mutations were also validated and confirmed somatic with Sanger
sequencing. However, the mutant allele was again absent in the cDNA level in both cases.
Finally, cBioPortal218, Catalogue of Somatic Mutations in Cancer (COSMIC)219, and International
Cancer Genome Consortium Data Portal (ICGC)220 were used to study the 33 hotspot mutations
across different tumor types and cell lines. In CRC, we found identical hotspot mutations in five
genes: ANTRX1, OR9Q2, CTTNBP2, HEXIM2, and PALD1. Although not identical, KCNB1 and
NLRP10 harbored mutations in the same codon as the discovery set hotspot mutations. Also, MORC2
mutations K27R and K27T were encountered. Two MSI CRC cell lines showed hotspot mutations:
HCT-15 in OR9Q2 and HCT-116 in HEXIM2. The search revealed also hotspot mutations in
extracolonic cancers in following genes: ANTXR1, CRYBB1, PALD1, SLC36A1, KCNB1, SETD9,
TMEM53, PTPRS, KRT82, PI15, and GALNT9 (see Supplementary Table S6 in the original
publication). As an example, among 64 MSI stomach cancers, we encountered a hotspot mutation in
ANTXR1, CRYBB1, and KNCB1. Although not frequent events, many of the hotspots occurred in a
wide spectrum of cancers.
3. Genetic and immune cell characterization of synchronous CRCs (III)
By exome sequencing 23 SCRC pairs with their corresponding normal tissues, we examined the
extent of genetic overlap within the pairs to study their similarities and differences and to assess
whether they share an origin or have grown independently. In addition, we carried out the first IS
analysis of SCRCs to study whether immune cell levels vary between synchronous tumors within a
patient.
3.1. Cohort characteristics
The majority (18/23, 78%) of the studied tumor pairs were MSS-MSS. In addition, there were three
MSI-MSI pairs and two cases where the MSI status differed within the pair. Most pairs (18/23, 78%)
resided on the same side of the colorectum: 13 pairs were left-sided and five right-sided. Besides one
patient from a LS family, other cases were assumed sporadic. In addition to the previously known
MLH1 mutation of a LS case, we found no known predisposing factors or clear candidate
susceptibility genes when studying the germline of the 23 SCRC cases.
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3.2. Lack of genetic overlap in paired tumors
By comparing the somatic mutation contents within the paired tumors, we discovered that most of
the mutations were unique, see Figure 6. Out of 23 pairs, only five (22%) shared at least one identical
mutation within the paired lesions. Two pairs were MSS-MSS and each pair shared one mutation.
The other three pairs were MSI-MSI that shared 12-39 mutations, mainly consisting of frameshift
mutations. In total, these shared mutations accounted for 0.4-1.1% of the mutations within the five
pairs.
Figure 6. The amount of shared nonsynonymous mutations in SCRC pairs. Nearly all mutations were
unique within the tumor pairs. Patient identifiers and the fraction of shared mutations are depicted above each
tumor pair. Inside each tumor is marked the number of nonsynonymous mutations they harbor. Hexagon =
MSI tumor, circle = MSS tumor. Reproduced from Hänninen et al. (2019), BJC, Springer Nature under the
Creative Commons Attribution 4.0 International (CC BY 4.0) licence.
Differences were seen also in other aspects, such as the number of nonsynonymous mutations. The
median difference was 44 mutations (interquartile range 15.5-71.8) per MSS-MSS tumor pair. Within
the three MSI-MSI pairs, the mutation count differed by 193, 359, and 902 nonsynonymous
mutations.
The mutation status of known CRC genes varied in many pairs (Figure 7). KRAS was mutated in only
one of the tumors in six (26%) pairs. Similar discordance in the mutation status was seen in BRAF,
another clinically relevant gene, that harbored a mutation in only one of the paired tumors in five
cases (22%). Such variation was noted also in other genes with potential clinical relevance, such as
PIK3CA (6/23, 26%) and PTEN (3/23, 13%). None of the studied cancer genes harbored similar
mutation patterns (mutated in one or both tumors within a pair) across all patients.
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Figure 7. Mutations observed in known cancer genes. Among the most frequently mutated known cancer
genes in the whole set were APC (33/47, 70%), TP53 (23/47, 49%), KRAS (18/47, 38%), TCF7L2 (11/47,
23%), and ACVR2A (10/47, 21%). MSI tumors are marked with red sample identifier. Hashtag refers to exact
same changes within tumor pair. Reprinted from Hänninen et al. (2019), BJC, Springer Nature under the
Creative Commons Attribution 4.0 International (CC BY 4.0) licence.
We then examined whether the tumors would share other mutated genes, concentrating on genes with
a truncating mutation in both tumors of a pair. Excluding the exact same changes and known cancer
genes listed in Figure 7, shared genes were found only in four pairs. One MSS-MSI pair had one gene
(FAM133A) in common, and the three MSI-MSI pairs shared 3-34 genes with truncating mutations,
consisting mainly of frameshift mutations. Variation was also detected in the number of overlapping
mutated known cancer signaling pathways (ATM, p53, Wnt/β-catenin, ERBB, PTEN, PI3K/AKT,
MAPK/ERK, and TGFβ). The number of overlapping altered pathways varied between one and eight
in a pair. Six pairs harbored mutations in all eight of the studied pathways in both tumors. The number
of mutated genes associated with the pathways, however, varied within these paired tumors.
3.3. Variation in the mutational signatures
Mutational signature analysis revealed four signatures: one specific to the patient, one related to MSI,
and two tumor-specific signatures (ts1 and ts2). The patient-specific signature resembled the known
age-related signature (signature 1) and the MSI signature the known MSI signature (signature 6)213.
The tumor-specific signatures did not clearly resemble any of the known signatures. The paired
tumors contained similar numbers of mutations contributing to patient-specific signature, indicating
that the tumors within a patient were of similar molecular age.
Tumors within pairs showed also variability in their signature contents. Regarding signature fractions,
the order of most contributing signatures differed within seven MSS-MSS pairs (7/18, 39%). Tumor
location did not seem to explain the differences since the majority (6/7, 86%) of the tumor pairs with
different signature order resided on the same side. Within 11 MSS-MSS pairs (61%) the signature
order was the same, with individual signature as the largest contributor in nine pairs and ts1 in two
pairs.
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To compare whether paired tumors resembled each other more than other tumors in the set in general,
the proportion of variation of the two tumor-specific signatures within pairs were compared to their
variation observed in the whole set. Ts2 was completely independent of the patient and in ts1 patient
identity explained only 8% of the variance.
3.4. Immune cell counts vary within paired tumors
Finally, we studied the immune cell counts by assessing IS in 19 SCRC pairs. IS4, the highest of the
IS category, was detected most frequently (IS0, 15%; IS1, 10%; IS2, 15%; IS3, 18%; and IS4, 41%).
Equal scores were seen within three (16%) tumor pairs. Therefore, the majority of pairs harbored
different IS. The score differed by one point in six pairs (32%) and by at least two points in 10 pairs
(53%). IS was not significantly correlated within the paired tumors (P = 0.837; Spearman’s rank
correlation coefficient). Clinicopathological variables, such as mutation count (P = 0.441; GEE with
ordinal response), diagnosis age (P = 0.339; GEE with ordinal response), or gender (P = 0.397; GEE
with ordinal response) did not seem to explain the differences within the tumor pairs. IS was not
associated with mutational signatures either (individual signature, P = 0.288; ts1, P = 0.151; ts2, P =
0.463; GEE with ordinal response). In general, immune response seemed to be stronger in MSI than
MSS tumors, although the difference was not statistically significant (P = 0.103; GEE with ordinal
response).
4. Exome-wide characterization of small bowel adenocarcinoma (IV)
4.1. Clinicopathological characteristics
106 SBAs were exome sequenced to comprehensively study the coding regions of these tumors for
somatic variation. The set included 26 (25%) duodenal, 52 (49%) jejunal, and 18 (17%) ileal tumors,
and 10 (9.4%) tumors had an unspecified location. The median age at diagnosis was 62 years. This
was lowest for patients with jejunal tumors (59.5 years versus 71 years for duodenal and 63 years for
ileal tumors; P = 0.00108, Kruskal-Wallis test). Four of the patients belonged to a LS family, two
patients had been diagnosed with FAP, ten with celiac disease, and six with an IBD. Based on the
exome data, 91 tumors were designated as MSS and 15 as MSI. MSI was associated with a better
disease-specific survival after adjustment for sex, age at diagnosis, and tumor stage (hazard ratio,
0.111; 95% confidence interval (CI), 0.0292–0.419; P = 1.20x10-3; Cox proportional hazards model).
Half of the tumors from celiac patients (five out of ten) were MSI and therefore celiac disease was
associated with MSI (OR, 8.31; 95% CI, 1.62–43.6; P = 4.83x10-3; Fisher’s exact test), in accordance
with previous studies.
4.2. Profile of key mutated genes
The average mutation burden was 4.30 mutations per megabase (mut/Mb) in MSS and 63.6 mut/Mb
in MSI tumors. Most frequently mutated known cancer genes in MSS SBAs were TP53 (44/91, 48%),
KRAS (43/91, 47%), APC (20/91, 22%), SMAD4 (14/91, 15%), SOX9 (11/91, 12%), BRAF (10/91,
11%), and ERBB2 (10/91, 11%). Of the known cancer signaling pathways, the most frequently
affected pathway in MSS SBAs was PI3K/AKT, having at least one gene mutated in most of the
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tumors (77/91, 84.6%). The next most frequently mutated pathways were ERBB (73/91, 80.2%),
MAPK/ERK (72/91, 79.1%), and Wnt/β-catenin (70/91, 76.9%). In MSI tumors, the most frequently
mutated known cancer genes included ACVR2A (13/15, 87%), BMPR2 (9/15, 60%), KRAS (8/15,
53%), and APC (7/15, 47%). Of note, TP53 and KRAS mutations in the whole set consisted mainly
of missense mutations (38/52, 73% and 50/52, 96%, respectively). Of these, most of the TP53 and all
KRAS missense mutations clustered in typical mutation hotspots. Most of the APC mutations (37/42,
88%) were protein-truncating. Two out of five (40%) patients with IBD harbored an APC nonsense
mutation.
Exome data allowed us to detect genes that showed statistical evidence of positive selection for
mutations in SBA. OncodriveFML identified 44 nominally significantly mutated genes (P < 0.05).
The following seven genes remained above the significance level after multiple testing correction
(false discovery rate, q-value < 0.1): TP53, KRAS, APC, SOX9, SMAD4, BRAF, and ACVR2A. All
genes with P < 0.05 were, however, considered potentially interesting. The list of 25 highest-ranking
genes is displayed in Table 5. In addition to the known cancer genes in SBA, the highest-ranking
driver candidates included recently reported (ATM and ARID2) and novel candidate driver genes (e.g.
ACVR1B, BRCA2, and SMARCA4).
Table 5. The 25 highest-ranking genes in MSS SBAs. OncodriveFML denoted the following genes as the
most relevant genes in the 91 MSS SBAs. Of these, TP53, KRAS, APC, SOX9, SMAD4, BRAF, and ACVR2A
remained significant also after correction for multiple testing. Reprinted under the Creative Commons






TP53 Tumor Protein P53 0.000001 42 43 38 5
KRAS KRAS Proto-Oncogene 0.000001 43 43 42 1
APC APC Regulator Of WNT Signaling Pathway 0.000001 21 29 21 8
SOX9 SRY-Box Transcription Factor 9 0.000001 11 12 4 8
SMAD4 SMAD Family Member 4 0.000034 14 17 15 2
BRAF B-Raf Proto-Oncogene 0.000467 10 10 10 0
ACVR2A Activin A Receptor Type 2A 0.00051 6 7 3 4
PIK3CA Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha 0.002106 7 7 7 0
PDYN Prodynorphin 0.002624 4 4 3 1
ATM ATM Serine/Threonine Kinase 0.003448 7 8 6 2
ARID2 AT-Rich Interaction Domain 2 0.005667 5 5 3 2
FBXW7 F-Box And WD Repeat Domain Containing 7 0.007291 5 5 4 1
ACVR1B Activin A Receptor Type 1B 0.007554 5 5 5 0
BRCA2 BRCA2 DNA Repair Associated 0.007599 4 4 3 1
FAM214A Family With Sequence Similarity 214 Member A 0.008006 4 4 3 1
TRO Trophinin 0.010371 4 4 4 0
DNMBP Dynamin Binding Protein 0.012701 4 4 3 1
ZSCAN1 Zinc Finger And SCAN Domain Containing 1 0.014597 4 4 4 0
ADAMTS18 ADAM Metallopeptidase With Thrombospondin Type 1 Motif 18 0.015212 5 5 4 1
MIB2 Mindbomb E3 Ubiquitin Protein Ligase 2 0.018198 6 7 7 0
FAM193A Family With Sequence Similarity 193 Member A 0.01966 4 4 3 1
PSME4 Proteasome Activator Subunit 4 0.021745 4 4 4 0
OR5M3 Olfactory Receptor Family 5 Subfamily M Member 3 0.022966 4 4 4 0
FRAS1 Fraser Extracellular Matrix Complex Subunit 1 0.024063 4 5 4 1
SMARCA4 SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of
Chromatin, Subfamily A, Member 4
0.025577 7 7 6 1
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4.3. Atypical BRAF mutation pattern
Ten MSS and one MSI tumor (11/106, 10.4%) harbored a mutation in BRAF, see Figure 8. However,
none of the mutations were V600E, the most common BRAF hotspot mutation in CRC. Instead, the
mutation pattern included two other known but less studied hotspots: G469A found in two tumors
and D594A/G/N in three tumors. Additionally, there were mutations located nearby (G466E, G596R,
and K601N). All of the above-mentioned mutations were located in exons 11 or 15 and have been
determined as somatic mutation hotspots in many cancers221. Read-level inspection uncovered one
additional tumor that displayed a hotspot mutation in G469A which had not been called. This tumor
also harbored another BRAF missense mutation. BRAF mutations included also two protein-
truncating mutations, Q257X and A404fs. Generally, BRAF V600E and KRAS mutations are mutually
exclusive. Here, four out of 11 BRAF mutant tumors harbored also a KRAS hotspot mutation.
Comparison of the tumor and patient characteristics between BRAF mutant and BRAF wildtype cases
did not display any significant differences.
Figure 8. Mutation observed in BRAF. We identified altogether 12 BRAF (ENST00000288602) mutations
in 11 tumors (10 in MSS and one in MSI). Reprinted under the Creative Commons Attribution (CC BY) license
from Hänninen et al. (2018), PLoS Genet, PLoS.
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4.4. ERBB receptor genes frequently affected
The most frequently mutated member of the ERBB receptor gene family was ERBB2, where
mutations were detected in 15 tumors (15/106, 14%), see Figure 9. Of these, ten were MSS and five
MSI. ERBB2 did not reach significance level in the OncodriveFML analysis but it is frequently
mutated in GI tumors, including SBA, and is a known therapy target45,115,152,221,222. Most of the
identified mutations (14/18, 78%) clustered into four known hotspots, S310F/Y, R678Q, L755S and
V842I. ERBB2 mutations seemed to be more frequent in MSI than MSS tumors (OR, 3.98; 95% CI,
0.886–16.4; P = 0.0368; Fisher’s exact test). Although with lower frequency, also the other three
members of the ERBB family were mutated in the set: EGFR in one tumor, and ERBB3 and ERBB4
in nine tumors. ERBB3 had two hotspot mutations - V104M/L found in three tumors and S864I in
two tumors. ERBB4 included one mutation hotspot, L897R/P, found in two tumors. Altogether 29
SBAs (27%) harbored a mutation in at least one of the ERBB genes. Hotspot mutations in different
ERBB genes were mutually exclusive, Figure 9.
Figure 9. Mutation pattern in ERBB2 and other ERBB receptor family genes. Mutations in ERBB2
(ENST00000269571) grouped into four mutation hotspots (above). Below, SBAs (n=29) displaying a mutation
in at least one member of ERBB receptor family genes are depicted in columns. All mutations are not shown
as some of the samples with a hotspot mutation harbored also another mutation in the same gene. Reprinted
under the Creative Commons Attribution (CC BY) license from Hänninen et al. (2018), PLoS Genet, PLoS.
4.5. Allelic imbalance events
AI analysis revealed a total of 840 gain and 1,541 loss events in the whole data set. MSI tumors
harbored a significantly lower number of events than MSS tumors (P = 1.95x10-9; 95% CI, 0.16-0.39;
negative binomial model). The most frequent AI event was partial or whole loss of chromosome 17p
which was detected in 62/106 (58.5%) samples. This region includes TP53 and non-synonymous
TP53 mutations co-occurred with the loss events in 41/50 (82.0%) of the mutated samples (OR, 7.43;
95% CI, 2.86-21.1, P = 4.02x10-6, Fisher’s exact test). Also, SOX9 (n = 44) and SMAD4 (n = 46),
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other significantly mutated known cancer genes, had a high frequency of chromosomal losses. Losses
of chromosome or chromosomal arm were frequent events (n > 30) at the loci 3p, 8p, 9q, 12q, 15, 17,
18q, 19, and 22. Whereas, chromosomes 13 and 8q harbored a high frequency of gain events. Clear
amplification was also seen in known cancer genes, such as KRAS (20/106, 18.9%), BRAF (19/106,
17.9%), and PIK3CA (16/106, 15.1%). Four samples showed a local amplification at the ERBB2
locus, two of which also harbored a concurrent ERBB2 hotspot mutation.
4.6. Mutational signatures
The mutational signature analysis was performed for all 106 SBAs. Signature 6, the known MSI
signature, was identified in the 15 tumors designated as MSI63. These tumors were grouped
separately, and the analysis was then repeated to the 91 MSS samples. This resulted in three
mutational signatures that corresponded to known signatures 1A, 17, and U2. We detected an
association between higher amount of mutations contributing to signature 1A and older age at
diagnosis (increase per 10 years, 20%; 95% CI, 10–32%; P = 4.32x10-5; negative binomial model),
similar phenomenon as seen in other cancers63.
4.7. Variation between tumors from different small bowel segments
Finally, we compared tumors from the three small bowel segments. The three tumor groups contained
rather similar mutation and AI counts, MSI frequencies, and mutated known cancer genes. However,
they also displayed differences. In MSS SBAs, APC mutation frequency was lower in jejunal tumors
(13.6%) compared to ileal (31.3%) and duodenal (37.5%) tumors. Whereas, TP53 mutation frequency
was lowest in duodenum (29.2%) followed by jejunal (56.8%) and ileal (56.3%) tumors.
Jejunal tumors showed the highest exposure to signature 1A. Compared to duodenal tumors, there
was a 66% increase of expected mutation count (95% CI, 29%-110%; P = 7.17x10-5; negative
binomial model). We observed no clear difference regarding signature 1A between ileal and duodenal
tumors (P = 0.348; negative binomial model).
Of the known cancer signaling pathways, ERBB signaling was the most frequently mutated pathway
in duodenal tumors (20/24, 83.3%). In jejunal and ileal tumors PI3K/AKT was the most frequently
affected pathway (42/44, 95.5% and 12/16, 75.0%, respectively). Overall, ERBB and MAPK/ERK
signaling displayed most notable differences between segments: ERBB signaling seemed to be less
frequently affected in ileal tumors (9/16, 56.3%) than those of duodenum (20/24, 83.3%) and jejunum
(38/44, 86.4%), (P = 0.0463, Fisher’s exact test). Whereas, MAPK/ERK signaling was more
frequently mutated in jejunal tumors (40/44, 90.9%) than duodenal (18/24, 75.0%) or ileal tumors
(9/16, 56.3%) (P = 9.06x10-3, Fisher’s exact test).
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DISCUSSION
1. ARID gene mutations in CRCs with microsatellite instability (I)
Molecular characterization of different tumor types has led to the identification of many driver genes.
Among them is ARID1A that has been recognized as a tumor suppressor gene in a variety of cancers.
ARID1A is part of the ARID domain containing gene family that consists of 15 genes. They all contain
a highly conserved ARID domain, bind to DNA either in a non-specific manner or specifically at AT-
rich sites, and are involved in cell proliferation control, tissue-specific expression, and
development38,223. Prior to our study, there had not been a systematic effort to study the mutation
profile of all ARID-encoding genes in any cancer type. Our aim was to investigate the mutation
spectrum and the role of ARID genes in MSI CRC.
Mining the exome data of 25 MSI CRCs, we found mutations in 12 out of the 15 ARID genes. Since
the high background mutation rate in MSI tumors makes the data analysis challenging we applied a
selection criterion of at least four mutated samples (including one nonsense or splice site mutation)
for genes to qualify for further analyses. Four genes, ARID1A, ARID1B, ARID2, and ARID4A,
fulfilled this criterion and emerged as the most potential candidates for additional studies.
ARID1A, ARID1B, and ARID2 encode for components of the large SWI/SNF chromatin remodeling
complex. Crucial function of the complex is to remodel nucleosomes and modulate transcription224.
Since ARID domain allows the complex to bind DNA, mutations in these genes might disrupt the
capability of the complex to bind DNA and regulate gene expression223. The SWI/SNF complex is
affected commonly in cancer as mutations, deletions, and translocations in different subunits have
been reported in around 20% of human tumors49.
ARID1A encodes for BAF250a, a key component of the SWI/SNF chromatin remodeling complex225.
ARID1A has emerged as a tumor suppressor with frequent inactivating mutations identified in e.g.
ovarian, gastric, and pancreatic cancer226–229. ARID1A was the most frequently mutated of the ARID
genes in our study displaying somatic mutations in 39% of tumors. The majority (63%) of the
nonsynonymous mutations were frameshift changes, typical of MSI tumors. Mutations occurred
along the length of the gene; a mutation pattern consistent with the reported spectra in other cancers.
One exception was a deletion of one base pair in a mononucleotide repeat of seven G’s in seven
samples. This represents a typical MSI target gene mutation and indeed this hotspot mutation has
been observed e.g. in MSI gastric cancer228. Some studies have reported a correlation between
ARID1A and TP53 mutations which varies, however, from an inverse relationship to a mutual
inclusivity49,230. We detected no correlation between these genes. However, due to small sample size,
no comprehensive conclusions could be made.
The driver role of ARID1A has been further affirmed by more recent studies, such as WGS efforts
on pancreatic and gastric cancers231,232. Although ARID1A harbors mutations in diverse tumor types,
these mutations occur often in a particular molecular or histological subtype, such as mutations
enriched in gastric cancer and CRC displaying MSI45,228 and ovarian clear-cell and endometrioid
carcinomas227. A study on mice showed that loss of ARID1A results in invasive colon tumors
exhibiting features associated specifically with MSI CRC233. They also observed that in the context
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of Apc-mutant mouse, ARID1A inactivation seemed to block tumor formation suggesting also a
possible oncogenic role for ARID1A in certain contexts. ARID1A mutations have also been suggested
to have a prognostic role as loss of ARID1A seemed to shorten time to cancer recurrence and cancer-
specific mortality234.
ARID1B encodes for BAF250b, a member of BAF variant SWI/SNF complexes and mutually
exclusive with BAF250a225,235,236. In our set, 13% of tumors harbored a mutation in ARID1B. Contrary
to ARID1A, the majority of the mutations were one base pair substitutions that resulted in one
nonsense and four missense changes. ARID1B mutations have been detected in different tumor types,
such as breast, liver, and clear cell ovarian cancers237–239. In addition, ARID1B deletions have been
observed e.g. in pancreatic cancer and childhood neuroblastoma229,240. ARID1B has been suggested
to repress Wnt/β signaling and thus inactivation of ARID1B could lead to elevated Wnt-dependent
transcription of target genes241.
Three out of six ARID1B mutated tumors in our study harbored also a mutation in ARID1A. ARID1A
and ARID1B mutations have been reported to co-occur and loss of ARID1A and ARID1B alleles have
been suggested to cooperatively promote tumorigenesis242. However, this study showed ARID1A-
deficient cancers to retain at least one functional ARID1B allele, suggesting a specific vulnerability
compared to the non-mutated cells. This synthetic lethal relationship has been observed also in other
studies and, in theory, could be used against ARID1A-deficient tumors by targeting ARID1B243. The
approach has, however, many challenges as ARID1B does not contain small molecule binding sites
and targeting ARID1B could increase cancer risk48. Also PARP inhibitors and anti-PD-L1 antibodies
have been suggested as potential therapeutic approaches for ARID1A-deficient tumors36,244. In
general, since many of the ARID1A mutations are inactivating and leading to loss of protein
expression, ARID1A presents a difficult therapy target.
ARID2 encodes a part of the pPAF complex, another member of the SWI/SNF chromatin remodeling
complex. The role of pPAF is to facilitate ligand-dependent transcriptional activation245. ARID2 was
first discovered as a putative tumor suppressor in hepatocellular cancer246. ARID2 mutations have
been reported in a variety of cancers, such as non-small cell lung adenocarcinoma, melanoma, and
pancreatic cancer247–249. In our sample set, ARID2 harbored a mutation in 13% of cancers. One
nonsense mutation located in the ARID domain and thus could potentially disrupt its DNA binding
ability. Subsequent to our study, ARID2 has been suggested as a potential driver also in duodenal
adenocarcinomas, papillary renal cell cancer, as well as hepatocellular cancer metastasis153,250,251.
Albeit at a low frequency, ARID2 was also significantly mutated in a pan-cancer analysis60.
ARID4A is a ubiquitously expressed nuclear protein. Together with other proteins it binds directly to
the retinoblastoma protein (pRB), a regulator of cell proliferation, and induces growth arrest252.
ARID4A was the second most frequently mutated gene (20%) of the four candidate genes. One of the
mutations located in the ARID domain. Prior to our study, ARID4A had been identified as a potential
tumor suppressor in leukemia and decreased expression of ARID4A had been detected in laryngeal
and oral tongue carcinomas253,254. More recently, studies have suggested ARID4A to also play a role
in gastric and prostate cancer255,256.
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In addition to ARID1A, also other members, ARID1B, ARID2, and ARID4A, were rather frequently
mutated in our set. Various types of mutations were present and scattered along the four genes, a
mutation pattern typical of tumor suppressors and what is previously reported in ARID1A. As
expected, little over one third of the mutations (38%) were frameshift changes. The mutation spectrum
we observed indicates that rather than affecting specific functions of the protein, mutations lead more
likely to partial or complete inactivation of the gene. These four genes appeared to be relatively
frequently mutated also in two large genome sequencing studies on CRC that included 23 and 15 MSI
CRCs45,114. Mutations in all four candidate genes were also found in MSS tumors of these studies,
although at lower frequencies. Overall, the presence of typical tumor suppressor mutation patterns in
genes previously associated with diverse cancer types suggests these genes may play a role also in
MSI CRC.
To our knowledge, this was the first systematic effort to study the mutation spectrum of the ARID
gene family. However, due to rather small sample size, this should be considered as a pilot study. The
possibility that some mutations are passenger events resulting from the MSI phenotype cannot be
excluded either. As another limitation to the study, larger structural alterations as well as non-coding
regions remain uncharacterized. Future studies are still needed to validate the function of these
mutations as well as better define the role of ARID genes in tumorigenesis.
2. New candidate oncogenes with mutation hotspots (II)
Most frequently mutated drivers have been discovered, however, the catalogue of mutations occurring
at intermediate or low frequencies is still incomplete45. To date, there are only a few established
oncogenes in MSI CRC. These include BRAF, PIK3CA, CTNNB1, and KRAS100. Oncogenes usually
present recurrent mutations in specific mutation hotspots and it has been stated that pattern, rather
than mutation frequency, should be considered when looking for significantly mutated genes4. In MSI
tumors, the challenge is to distinguish true drivers among the passenger mutation load. These tumors,
however, may provide a sensitive model system to detect novel oncogenic mutations by generating
frequent mutations for possible selection during tumor progression. Since mutation hotspots are
thought to be markers of positive selection in tumorigenesis, we hypothesized that by searching for
these very specific mutation patterns we could detect new candidate oncogenes.
In this study, we sought to identify novel oncogenic driver genes by using exome data on 25 MSI
CRCs and the corresponding normal samples as the discovery set. We identified 33 novel candidate
oncogenes recurrently mutated at the same positions. Fourteen genes (ANTXR1, CEP135, CRYBB1,
MORC2, SLC36A1, GALNT9, PI15, KRT82, CNTF, GLDC, MBTPS1, OR9Q2, R3HDM1, and
TTPAL) harbored hotspot mutations also in the validation set. Of these, ANTXR1 stood out as the
most frequent target of hotspot mutations (2.8%). Two validated hotspots (MORC2 S25A and OR9Q2
A249T) were also found in one of the 10 studied CRC cell lines. In addition to CRC, a number of the
33 novel hotspot mutations were encountered in various extracolonic cancers. Albeit with low
frequency, these hotspot mutations could have a role in the genesis in numerous cancers.
ANTXR1 (also named TEM8) encodes for a single-pass cell-surface protein that was first identified
to be overexpressed on the tumor vasculature in human CRC and has been shown to play a role in
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tumor angiogenesis257,258. TEM8 antibodies were also shown to exhibit antitumor activity in several
different tumors in mice258. Subsequently, ANTXR1 has been shown to be overexpressed also on
cancer cells in a variety of tumors, such as breast, neuroblastoma, and melanoma259–261. ANTXR1 has
also been suggested to function as a biomarker of pancreatic ductal adenocarcinoma and triple-
negative breast cancer stem cells262,263. Recently, studies have indicated overexpression of ANTXR1
to be a potential target for immunotherapy in triple-negative breast cancer and gastric cancer264,265.
The biological function of ANTXR1 combined with the observed mutation pattern makes ANTXR1
the most potential candidate oncogenic driver in MSI CRC. Even though we found no expression of
the mutant allele in the mature cancers, which makes the hotspot in question not an attractive therapy
target per se, the exact mechanisms of the involved tumorigenesis are intriguing for further cancer
biology research.
Also other genes highlighted by our study have been studied further in regards to their involvement
in cancer. MORC2 has been reported to facilitate ATP-dependent chromatin remodeling in response
to DNA damage and to be upregulated in many cancers266,267. Studies have also suggested MORC2
to promote genesis of e.g. gastric, breast, and liver cancers and contribute to the metastasis
development in triple negative breast cancer268–271. Another example, Glycine Decarboxylase
(GLDC), has been reported to be upregulated in many cancer types and one preclinical study
suggested GLDC as a potential therapeutic target in non-small cell lung carcinoma272. Suppression of
GLDC has also been indicated to suppress tumor cell growth in various cancer cell lines273. Whereas,
expression of GLDC has been shown to associate with melanoma prognosis274. Also Alpha
Tocopherol Transfer Protein Like (TTPAL) has recently been suggested to promote colorectal
carcinogenesis275. They also associated TTPAL overexpression with worse survival.
Considering the strict criteria used in this study to define a hotspot mutation, the seemingly low
mutation frequencies are not that surprising. As a comparison, CTNNB1 and KRAS harbored hotspot
mutations with the frequency of only 8% and 4% respectively in the discovery set (see Table 6).
Subsequently, we have further characterized the SNV mutations in the discovery exome data set
together with additional 12 genome-sequenced MSI CRCs276. The ranking of the top 72 most
significantly mutated genes included three of our novel candidate oncogenes, CMTM2, CRYBB1, and
SLC36A1. The effort also entailed the identification of additional potential oncogenes with a hotspot
mutation. This yielded another seven novel candidates.
Table 6. Hotspot mutation frequencies of known oncogenes in the study and examples of the reported
mutation frequencies of these genes in MSI CRC. Of note, the frequencies are not fully comparable due to
varying sequencing targets: Mirabelli-Primdahl et al.277 and Rajagopalan et al.278 included most frequently
mutated exon(s), Corso et al.279 a mutation hotspot or two of the most frequently mutated exons, Lin et al.141 a
























BRAF 32% 42% NA 31% 16% 34% 53%
PIK3CA 20% 17% NA NA 7.9% 34% 38%
KRAS 4% 15% NA 43% 21% 31% 21%
CTNNB1 8% 6.9% 25% NA NA 3% NA
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As to limitations of this study, it was conducted with a relatively small sample set and thus should be
considered as a pilot study. We identified a set of candidate driver oncogenes, however, with this
targeted approach other potential oncogenes activated by alternative ways remain uncharacterized.
Furthermore, tumor heterogeneity and microenvironment are known to create challenges in mutation
discovery. Further work on the characterization of the identified hotspot mutations in different tumor
types together with functional experiments are still required to elucidate their part in tumorigenesis.
For improving diagnostics, new therapeutic interventions, and personalized care, it is essential to
gather comprehensive knowledge on the spectrum of mutations in human cancers. In general,
mutation hotspots in driver oncogenes create attractive therapeutic targets for small-molecule
inhibitor drug development. For example, BRAF V600E mutations have been successfully utilized as
a treatment target for patients with metastasized melanoma281. Often, however, targeted
monotherapies fail to cure the patient due to pre-existing subclones that are resistant to the
treatment282. Most cancer driver genes mutated in most patients occur at intermediate-frequency level
(2-20%)60. Thus, it is of utmost importance to characterize and understand the role of these less
frequently affected genes in tumorigenesis as well in order to provide therapeutic options for a larger
number of patients and identify targets for combination treatment protocols. Here, MSI CRCs were
used as a platform to find novel candidate oncogenes. Some of the hotspot mutations were also present
in a small percentage of other tumors, implying they could play a role in a variety of tumor types. The
catalogue of these mutation hotspots should serve as a valuable resource for further cancer research.
3. Synchronous CRCs within a patient display substantial variety (III)
Although SCRCs account for only a small fraction of CRC cases, given the prevalent nature of CRC,
SCRCs represent a fairly frequent clinical challenge. Since the paired tumors arise in a common
background of genetic and environmental factors, SCRCs present a unique model to study CRC
genesis. Studies on SCRC have previously focused mainly on clinicopathological features and single
genetic factors, such as the MSI status and known cancer genes including APC, KRAS, and BRAF.
The underlying molecular mechanisms in SCRC have not been thoroughly investigated. We were
therefore compelled to study these tumors in a more comprehensive manner. We exome-sequenced
23 tumor pairs and their corresponding normal tissue to evaluate the extent of their genetic overlap.
Additionally, we analyzed the interplay between the mutation profile and immune cell invasion in the
paired tumors. Based on clinical information, besides one case with Lynch syndrome, patients did not
harbor any clear high risk factors for CRC.
First, we aimed to understand whether these simultaneous tumors share a common origin, or have
they arisen independently. Based on the exome data, only five out of 23 pairs displayed one or more
exact same genetic changes within them. Of the five pairs, three were composed of MSI-MSI tumors
where the shared mutations accounted for only a small fraction of the mutations and represented types
of changes commonly found in MSI tumors. The other two pairs were MSS-MSS and both pairs
shared one mutation. One of these was a known mutation hotspot in APC, shared probably by
coincidence. The lack of genetic overlap strongly suggests these paired tumors have independent
origins.
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While our study was ongoing, three other studies reported features of SCRCs based on exome-
sequencing data283–285. In general, the median mutation counts per tumor (88.5 for MSS and 933 for
MSI) were in line with these studies and what has been reported for solitary CRC45,283–285. Our results
were in agreement with these three other exome studies that, in general, supported the idea of separate
genetic origins. Whereas, one SNP study reported a subset of SCRCs to be monoclonal286. Single
studies on synchronous tumors of other anatomical sites, such as lung and kidney, have shown these
tumors to also display genetic heterogeneity287,288.
Second, we wanted to explore whether the paired tumors would otherwise harbor similarities. We
observed differences in the mutation statuses of the known CRC genes within pairs which is in line
with previous results283–285,289. Further differences were seen when searching for other genes with
possibly damaging truncating mutations in both tumors of a pair. This resulted mainly in genes with
frameshift mutations in repeated sequences of MSI-MSI tumor pairs. These mutations had probably
arisen by chance due to the replication errors characteristic of MSI tumors. The data suggested that
the paired tumors might also utilize different signaling pathways. In general, genetic diversity was
seen in all tumor pairs, regardless of a known predisposition syndrome background, the presence and
number of adenomas, location of the tumors, or their distance from each other. In addition, the search
for possible predisposing genetic factors did not result in any clear candidate genes.
We performed mutation signature analysis to evaluate whether the paired tumors in the same
environment have developed through similar mutational processes. When looking at signature ts1,
the paired tumors did resemble each other somewhat more than other tumors in the set. Whereas,
signature ts2 did not differentiate whether the tumors belonged to the same patient. In general, the
MSS tumors harbored similar signature contents both within the pairs and between patients. However,
within over one third of the pairs the composition of mutation signatures differed. Therefore, these
tumors might have undergone different mutational processes.
To further characterize the similarities and differences within tumor pairs, we assessed the immune
infiltrate in the tumors by IS in 19 pairs. The combination of immune score and TNM classification
and/or defined MMR status in CRC has been proposed to predict survival and therapy
response88,89,216,290. There was no previous knowledge on how immune responses and thus immune
cell levels vary within paired lesions in a patient. We observed that the intratumor immune reaction
varied between cases and, in the majority of them, also within the tumor pair. Clinicopathologic
features, such as mutation count, MSI status, or tumor location, did not clearly explain this variation.
The immune reaction is thought to be affected by several factors, such as the tumor
microenvironment, both genetic background of the patient and the genetic content of the tumor, and
gut microbiota89.
Studies have reported synchronous tumors to differ from solitary tumors. When compared to solitary
tumors, the fraction of MSI tumors among SCRCs was slightly higher (22% vs. ~15%) which is in
agreement with previous studies24,81,83. Some studies have reported mutation rate of known CRC
genes, such as BRAF, SMAD4, PIK3CA, and NRAS, to vary in SCRCs compared to solitary tumors.
We did not detect any clear differences.
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The observed variation within paired tumors might affect genetic testing and therapeutic strategies.
The results strengthen the concept that, for optimal outcome, both tumors should be considered when
screening for drug targets or predictors of therapy response, such as KRAS, NRAS, BRAF, and
PIK3CA. Many tumor pairs harbored a mutant KRAS in only one of the tumors - a situation where
only one of the tumors might respond to anti-EGFR treatment. Although it has been suggested that,
within a patient, a large majority of driver gene mutations are common to all metastatic lesions and
thus a biopsy from a single metastasis represents accurately most of the functionally important
mutations, synchronous primary tumors might present a more convoluted scenario as the metastases
might have arisen from either of the genetically distinct tumors291. Some patients in our study
displayed a pair of MSI-MSS tumors, indicating that the neoantigen levels might vary between
tumors. This might have relevance if immune checkpoint inhibitor therapy is considered as a potential
treatment. Incorporating IS as a measure of immune response might provide additional information
on tumors that could respond to immune modulating therapy.
The study had some limitations. The research material included DNA extracted from FFPE material.
Although steps were taken to ensure the efficient removal of possible false calls, we recognize that
the data might still contain some low-frequency artefacts. However, these should not affect the main
conclusions of the study as the aim was to compare paired tumors exome-wide and the mutations of
the main interest were of good quality. Despite exome sequencing being highly informative, we were
not able to study the non-coding genomic regions or epigenetic changes, such as gene methylation.
Thus, it remains unknown what is their contribution to tumor multiplicity. Field effect has been one
factor theorized to have an impact on tumorigenesis of synchronous tumors. In many cases the tumors
were found on the same side of the colorectum and several patients had at least one additional
adenoma. These might imply possible regional field effect. Some studies consider synchronicity as
tumors that have appeared within a 6-month period. Among the strengths of this study, we
concentrated solely on synchronous tumors that have been diagnosed simultaneously. Additionally,
by analyzing tumors exome-wide, instead of concentrating on targeted genes, we were able to obtain
a more comprehensive view of their genomic diversity.
In summary, we observed different mutation patterns with only a few shared mutations within paired
tumors. This proposed a parallel evolution of SCRC without a common origin and thus confirmed
previous observations. The mutation frequencies of known CRC genes resembled those seen in
solitary CRCs, while some differences exist between previous studies on SCRC. Our study elucidated
further the genetic background of SCRC and how immune responses varied within paired lesions.
Regardless of their shared environment, CRCs that are found simultaneously within the patient
exhibit great genetic variety and thus it is essential to examine both tumors when designing treatment.
Additional studies are still needed to further explore the causes for tumor multiplicity.
4. Somatic mutation landscape of SBA (IV)
Our understanding of cancer genetics on multiple tumor types has rapidly increased with the
utilization of NGS tools. Yet, due to their rarity, some cancer types remain less studied. One of such
is SBA, an aggressive disease with limited treatment options. Prior to our study, relatively few large-
scale studies on SBA had been conducted. These have either screened a set of known mutation
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hotspots or cancer genes or exome-sequenced small sets of duodenal adenocarcinomas115,120,152–154.
Since its incidence is rising and no evidence-based treatment recommendations have been available,
there is a dire need for more knowledge on SBA biology. Thus, we conducted the thus far largest
exome sequencing effort on a nationwide population-based SBA sample collection in order to
characterize the common genetic changes occurring in this tumor type. This unique cohort included
altogether 106 primary SBAs including tumors from all three small bowel segments.
The median mutation burden in the whole set was 3.96 mut/Mb which is in agreement with previous
studies on SBA and similar to that seen in gastric cancer and CRC67,115. The fraction of MSI tumors
were also similar in these tumor types45,222. We confirmed in a large set of SBAs that, as in CRC,
MSI correlates with longer disease-specific survival also in SBA292. This was detected also in a more
recent study293. Patients with MSI tumor might benefit from immunotherapy, suggesting a potential
role for immunotherapy also in a fraction of SBA patients92.
Exome data enabled us to search for genes that showed statistical evidence for positive selection in
SBA. The most significantly altered genes in MSS SBA included TP53, KRAS, and APC. These genes
were also frequently mutated in MSI SBA. AI analysis provided further support for the pivotal roles
of these genes in SBA genesis, as high frequency of losses in TP53 and APC and gains in KRAS was
observed. The mutation frequencies of TP53 and KRAS corresponded to what have previously been
reported on SBA115,120,152. Compared to CRC and GA, TP53 displayed similar mutation frequencies,
whereas KRAS mutation frequencies resembled that of CRC but were clearly higher than in GAs45,222.
KRAS has clinical relevance as mutations in this gene predict lack of response to EGFR inhibitors 294.
Additionally, the role of anti-EGFR therapy in RAS wild-type SBA has been suggested to be unclear
based on a small clinical trial where treatment showed no response91,295.
The role of APC mutations in SBA genesis has been under debate and it has been proposed that it
would not be as essential as in CRC296–298. Especially, the lack of nonsense mutations has been
reported. APC was relatively frequently mutated in our set, as reported in recent studies115,153.
Furthermore, the majority of the observed mutations were protein-truncating. APC mutation
frequency increased along the GI-tract, confirming previous findings115. Although the overall
mutation frequency of APC was lower than in CRC, our results support the importance of APC also
in the SBA pathogenesis. APC mutations had also been suggested to occur exclusively in SBA
patients without IBD115. Our results implied, however, that a subset of SBAs with IBD background
can harbor inactivating APC mutations.
Among the highest-ranking genes was also BRAF. Interestingly, we detected no V600E mutations,
the most common hotspot for mutations e.g. in CRC. Instead, we observed an atypical hotspot pattern
with mutations clustering in two other hotspots nearby. These were present exclusively in MSS
tumors, as previously indicated in CRC299. These hotspots have been reported commonly in some
tumor types, such as in lung adenocarcinomas and melanoma300. Four SBAs harbored both BRAF and
KRAS mutations. This could at least partly be explained by the fact that three of these BRAF mutations
were likely kinase-silencing or truncating changes. Co-occurrence of kinase-impaired BRAF and
mutant KRAS has been observed in various cancers299–301. Shrock et al. reported only a minority of
BRAF mutations in SBA to be V600E, together with our results highlighting the importance of
atypical BRAF mutations in SBA115. Metastatic CRC harboring such atypical mutations have been
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shown to have distinct clinicopathological features and improved OS compared to BRAF V600E
mutant CRCs118. How different non-V600 BRAF mutants respond to therapy is currently under
investigation. Overall, these results suggest that screening also for atypical BRAF mutations might be
clinically relevant for guidance of personalized treatment plan.
In addition to the known cancer genes in SBA, the most relevant genes on exome-wide analysis
included other recently reported and novel candidate driver genes. One recently reported candidate
driver gene in SBA was ATM, a suggested barrier to dysplastic growth in bowel tumors and a
potentially clinically relevant biomarker to predict PARP inhibitor sensitivity302. Another recently
suggested potential driver in SBA was ARID2, frequently mutated in various cancers and further
discussed above (section 1 of Discussion)153. The novel candidate drivers in SBA identified by this
study, ACVR1B, ACVR2A, BRCA2, and SMARCA4, have been implicated previously as driver genes
in many other tumor types. The mutation status of these novel candidate drivers might be clinically
relevant due to their potential role as drug targets and/or predictors of therapy response. As an
example, somatic BRCA2 mutations in melanoma have been found to correlate with anti-PD-1
responsiveness303. Also, drugs targeting BRCA2 are already being developed. SMARCA4 is a key
SWI/SNF chromatin remodeling gene224. Due to its tumor suppressive role, SMARCA4 is not an ideal
drug target. However, a recent study proposed that, due to synthetic lethality, CDK4/6 inhibitors
might be effective against SMARCA4-deficient tumors304.
The members of the ERBB gene family, EGFR, ERBB2, ERBB3, and ERBB4, are commonly
amplified, overexpressed, or mutated in various malignancies305. Of these, ERBB2 was the most
frequently altered (14%) in our set. Unlike in CRC, ERBB2 mutations were mainly point mutations.
We detected four known mutation hotspots, of which one had not previously been reported in SBA.
Additionally, we identified localized and strong amplification of ERBB2 in four samples. Two of
these harbored also a hotspot mutation. The other gene family members were less frequently mutated
(0.9-8.5%). Both ERBB3 and ERBB4 harbored one hotspot. These hotspots have been previously
identified in e.g. CRC and gastric cancer but, to our knowledge, not in SBA306. ERBB family
members have potential clinical relevance and targeted therapies are under development. In fact,
multiple drugs targeting ERBB2 and EGFR receptors are already in clinical use. Based on our results
together with other reports, of these genes especially ERBB2 could be considered as a potential
therapeutic target in SBA115,152,307. Furthermore, a recent preclinical study suggested that ERBB2
tyrosine kinase inhibitors could play a role in the management of SBA308.
In addition to searching for single genes and possible therapy targets, we examined the tumor set for
most frequently affected, well-known cancer related pathways and performed the first comprehensive
mutation signature analysis of SBA. Overall, the most commonly affected pathways in MSS SBA
were PI3K/AKT and ERBB signaling. Some variability between segments were noted, e.g. ERBB
signaling was the most frequently affected pathway in duodenal SBAs and PI3K/AKT signaling in
jejunal and ileal SBAs. More studies are needed, however, to clarify these differences in more detail.
Mutational signature analysis revealed four signatures: 1A, 17, and U2 in MSS and 6 in MSI tumors.
We observed segment-wise variation regarding signature 1A. The amount of signature 1A exposure
has been shown to associate with older age at diagnosis63. Signature 1A exposure was associated with
jejunal location, regardless that the patients with jejunal tumors were, on average, younger. One
reason for this could be possible regional differences in DNA methylation or in the cell division rate
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between small bowel segments. Based on mutational signatures, SBAs seem to closely resemble CRC
as the majority of their associated signatures overlapped63. This could reflect them possibly sharing
similar exposures, although the small bowel and colorectum represent different environments.
As a strength of our study, by obtaining registry-based data together with comprehensive
clinicopathological data on all SBA cases, we were able to collect a large, population-based dataset.
This included tumors from all three segments of the small bowel with defined location, allowing us
to examine the differences between these subsets. Exome data allowed us to elucidate the molecular
basis of SBA but, as a limitation, we were not able to study the non-coding region of the genome nor
the epigenetic changes. We also acknowledge that, regardless of the strict filtering, the data may
contain some rare germline mutations or low-frequency artefacts due to FFPE material. Despite the
rather large dataset, we were not able to detect any obvious genetic reason for the difference in
incidence between SBA and CRC.
To our knowledge, this was the first large-scale exome study conducted on SBAs. Taken together,
these results indicate that SBA is a distinct tumor type with its unique set of significantly mutated
genes. Heterogeneity in the mutation landscape indicates that several driver genes can affect SBA
genesis. There may also be some variation between tumors originating from different segments. One
of the clearest differences from CRC was the BRAF mutation spectrum which might be relevant when
designing genetic testing and treatment of SBA. The results highlighted many potential treatment
targets, both currently targetable (ERBB2, BRAF, and BRCA2) as well as new candidates (including
ERBB3, ERBB4, ATM, ACVR2A, ACVR1B, and SMARCA4). Especially alterations in ERBB2 and
BRCA2, atypical BRAF hotspots, and MSI status have been discussed as options for more
personalized treatment in SBA also more recently91,307,308. Thus far SBA has been treated following
the same regimen as CRC in the advanced setting. These recent advances in characterizing SBA have
led to improved understanding of the tumor type and to the first set of National Comprehensive
Cancer Network (NCCN) guidelines for the treatment of SBA, published autumn 2019309. Further
research is, however, required to obtain a better understanding of SBA. Finally, studies such as this
are good examples that exome-wide characterization of a rare tumor type can provide more
knowledge for the basis of more personalized treatment and thus should be considered valuable in
other rare tumor types as well.
5. Toward future cancer treatments
Exome sequencing has enabled us to examine simultaneously the whole coding region of the genome
with a reasonable price. By utilizing this technology, we have provided many potential novel drivers
as well as further knowledge on tumor biology of bowel tumors. Examples of clinically relevant
findings in this thesis work include the observed differences in SCRC pairs that can affect the
treatment planning for patients with SCRC and assessment of the mutation landscape of SBA that
indicate genetic screening for eg. atypical BRAF mutations to be beneficial for optimal treatment. A
comprehensive view on genetic changes underlying tumorigenesis is needed to improve treatments
as well as preventive measures. Knowledge on mutation content directs targeted treatment planning
as well as helps identifying new potential candidates for drug development targets.
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Through advancements of sequencing technology, research has also uncovered frequent mutations in
genes involved in processes previously not associated with cancer and thus provided novel options to
pursue in treating tumors more efficiently. One example is chromatin-related proteins, identified to
be affected in over 50% of cancers310. In this study, we also detected multiple altered genes that
encode for chromatin remodelers, such as ARID1A, ARID1B, ARID2, SMARCA4, and MORC2. We
observed great heterogeneity in the mutational landscape of the bowel tumors indicating that many
driver genes play a role in their biology. Since most cancer driver genes are known to be mutated at
intermediate or lower frequencies, as also observed here, the characterization of these genes continues
as an important effort to be able to provide optimal therapeutic options for a larger number of patients
and more effective combination treatments. In the future, larger datasets and more advanced
technologies, such as WGS and third-generation sequencing, aid in taking this effort forward. By
understanding the molecular pathogenesis of bowel tumors paves the way towards identification of
druggable targets with the goal to ultimately benefit the patients.
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CONCLUSIONS AND FUTURE PROSPECTS
CRC is one of the most common cancers and due to extensive research, it is one of the best
characterized tumor types. The most frequently mutated driver genes have been discovered but more
insight is still needed on genes mutated with moderate or low frequency that contribute to
tumorigenesis. Despite the rapid accumulation of knowledge on the genetic changes in CRC, until
recently the clinical utility of molecular data has been rather limited. Specific CRC subtypes also
require more research. As an example, MSI tumors represent a molecular subclass of CRC, where the
detection of driver genes has been challenging and only few oncogenes are known. A subset of CRCs
can also occur as multiple primary tumors residing in one patient. Increasing knowledge on the
mutation content of these synchronous lesions helps to illustrate how they have arisen and how these
cases should be treated. In contrast to CRC, SBA is a rare tumor type and thus less is known of its
genetic background. It is an aggressive disease and there is a dire need for better understanding of its
molecular characteristics. NGS has enabled the sequencing of large tumor sets and thus facilitated a
more comprehensive view of the driving forces behind tumorigenesis. Large-scale genetic
information together with clinicopathological data provides opportunities to understand the biology
underlying tumor development and guides the development of treatments.
The aim of this thesis was to provide new insights into the molecular genetic background of CRC and
SBA. Focus of studies I-II was on somatic mutations in MSI CRC to identify novel candidate driver
genes, study III concentrated on understanding whether SCRCs within a patient resemble each other
genetically and study IV aimed to characterize the somatic mutation content of SBA.
I
In study I, in order to examine the role of ARID gene family in MSI CRC, we characterized the
mutation spectrum of these genes in 25 MSI CRCs, followed by a further analysis of the four most
prominent candidate genes in an additional set of 21 MSI CRCs. We confirmed that ARID1A is
frequently mutated in MSI CRC. In addition, ARID1B, ARID2, and ARID4A were rather frequently
mutated and could represent potential candidate driver genes in MSI CRC. Altogether 61% of the
patients had a tumor with a mutation in at least one of these four genes. This was the first attempt to
characterize the mutations of the whole ARID gene family. In the future, functional efforts are needed
to determine the mechanistic details of how these mutations might contribute to tumorigenesis.
Additionally, further research is required to better define the role of ARID genes in various cancer
types. Should alterations in these genes be involved in the development of MSI CRC and other tumor
types, they could be utilized as predictors of therapy efficacy as well as in the development of targeted
drug therapies.
II
Only few oncogenes are known in MSI CRC. Thus, in study II, we aimed to identify novel candidate
oncogenes by searching for genes with somatic mutation hotspots. This mutation pattern is typical of
oncogenes, a sign of selection in tumor development, and an attractive target for drug development.
Exome sequencing data from 25 MSI CRCs and their corresponding normal tissues revealed 33 novel
candidate oncogenes with a recurrent mutation hotspot. Of these, 14 displayed additional hotspot
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mutations in a validation set of 254 MSI CRCs. Among them was ANTXR1 that emerged as the most
prominent candidate of the study. It is unknown why the hotspot mutations were not selected for in
the mature tumors and further efforts are needed to understand the biological background of the
phenomenon. In general, upregulation of ANTXR1 has been suggested to promote tumor growth and
progression311. Additionally, many therapies targeting ANTXR1 have shown anti-tumor efficacy in
preclinical models.
These findings underline the notion that CRCs are heterogeneous tumors whose mutation landscape
comprises few frequently affected genes and many less frequently mutated genes. It is of great
importance to continue creating a catalogue of driver genes in order to further characterize
dysregulated pathways and potential drug targets. In this study, altogether 14% of the patients had a
tumor that harbored at least one of the novel hotspot mutations and could potentially benefit from a
targeted treatment. In the future, additional studies are needed to validate these findings in
independent tumor series. Furthermore, functional efforts are necessary to thoroughly understand
their pathogenic role in carcinogenesis. Taken together, this study uncovered a variety of novel
recurrent candidate oncogene mutation hotspots to be further scrutinized as potential therapeutic
targets.
III
In study III, in order to estimate the genetic overlap within SCRCs, we exome-sequenced 23 paired
tumors and their corresponding normal samples. This study revealed great heterogeneity between
SCRCs within each patient implicating that, despite similar environment and genetic background,
these tumors may be driven by distinct molecular events and develop independently. In addition to
the lack of shared somatic mutations, the amount of genetic overlap varied in other aspects such as
mutation statutes of known CRC genes and signaling pathways. By analyzing IS, we observed that
there was also variation in the immune reaction between patients and, in most of the cases, also within
paired tumors.
Our study confirmed previous observations and elucidated further the genetic background of SCRC
and variation of immune responses within tumors, improving our understanding of the diversity
within SCRCs. These results strengthen the notion that SCRCs harbor variation in common drug
targets as well as other potential targets, mutation burden, and single genetic changes that might affect
response to treatment. Such variation within paired tumors included eg. the discordant MMR status
that affected around 9% of the patients and the discordant KRAS mutation status that was present in
26% of the cases. Thus, this study should provide valuable information for the clinical management
of patients with SCRC. Therapeutic decisions, especially regarding targeted therapies, should
consider SCRCs as individual cancers and thus all lesions should be analyzed for optimal treatment
outcome. Further studies are, however, still needed to decipher the reasons for tumor multiplicity.
IV
In study IV, in order to gain better understanding on the molecular genetic background of SBA, we
gathered and analyzed a unique, population-based set of 106 primary SBAs, thus far the largest exome
set of this tumor type. Our study confirmed the role of known drivers in this cancer as well as recently
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reported potential drivers, and implicated possible novel drivers. The data showed some differences
between SBAs from the three small bowel segments; however, the relevance of these differences
requires further studies. Based on the results, SBAs harbor both similarities and differences with
CRCs. The proportion of MSI tumors, mutation frequency of certain driver genes, and mutation
signature content resembled those of CRC. MSI screening could thus also be warranted in SBA in
view of immunotherapy. Whereas, notable differences were seen in e.g. potentially clinically relevant
aspects between SBA and CRC, such as the atypical mutation spectrum of BRAF and the ERBB2
mutations consisting mainly of point mutations. This study provided information also on other
potential therapeutic targets or predictors of therapy response. Overall, comprehensive
characterization of SBA yielded new and more thorough insights into the genetic background of this
tumor type, providing further evidence that SBA is a genetically distinct tumor type. In the future,
further validation of the findings in other sample sets and functional validation is warranted to
thoroughly understand their role in SBA genesis. Altogether, this study improved our understanding
of SBA biology that should ultimately be useful for the management of this cancer.
Future prospects
Over the past two decades, the field of oncology has undergone conceptual revolutions that have
shaped our understanding of cancer. One enormous step forward has resulted from international
efforts to sequence a large amount of cancers with base-by-base accuracy to obtain a comprehensive
view on carcinogenesis. The development of high-throughput technologies and decrease in their costs
have enabled the increase in sequencing intensity. This has resulted in vast amounts of information.
Integration of mutation data with other data types, such as epigenomic (e.g. DNA methylation) and
transcriptomic (mRNA and protein expression) data, has enhanced our ability to interpret the potential
biological role of the identified alterations, including those of unknown significance. Furthermore,
emerging technologies have brought novel ways to study tumorigenesis. Recent advances include
third generation sequencing, also called long-read sequencing, that allows e.g. the detection of
complicated structural changes on a haplotype level, single-cell sequencing that provides more
detailed insight into tumor heterogeneity, CRISPR-Cas9 genome editing that enables the functional
characterization of mutations, and methods, such as Hi-C and ATAC sequencing, that are used to
study the regulatory genome.
Although deciphering the molecular pathogenesis of cancers is advancing, there are many challenges
in designing targeted therapies. Most prevalent oncogenic mutations are currently undruggable. Thus,
in addition to finding means to target these changes, identifying new targets is of great importance.
Genes with mutational hotspots, as an example, represent attractive therapy targets. Also tumor
suppressors, in general, depict a challenging treatment target, since driver mutations in these genes
lead to functional loss of the protein. However, the search for alternative routes is ongoing. One
suggested approach is synthetic lethality that is successfully used to target BRCA deficient breast and
ovarian tumors with PARP inhibitors312. Furthermore, recent technical advances, such as the above-
mentioned CRISPR-Cas9-based gene editing, have enabled more systematic screening of potential
synthetic lethal drug targets313. Other therapeutic strategies are also being developed, such as targeting
chromatin remodelers and harnessing the patient’s own immune system310,314.
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Further challenges in treatment are introduced by tumor heterogeneity which both generates primary
drug resistance and is the basis for genetic tumor evolution that drives secondary resistance.
Understanding the critical signaling pathways for tumorigenesis is one of the main goals to target a
wide range of tumor cells4. Signaling pathways, however, function differently in different tissues and
thus a drug that is efficient in a certain tumor might not bring benefit in another. Such an example is
vemurafenib that is successfully used in metastatic melanoma with BRAF V600E mutation but has
no therapeutic effect in metastatic CRC harboring the same mutation315. Drug efficiency can also be
affected by other accompanying genetic alterations (both germline and somatic) and tumor
microenvironment. Thus, better understanding of the mutation content in different tissue contexts will
enable more efficient targeted therapies. On the other hand, cancer subclasses arising from different
tissues can also harbor similar molecular features316. Therefore, integration of diverse sets of cancers
and grouping them based on their molecular relationships instead of anatomical location can be
beneficial when exploring novel clinically actionable targets.
Cancer continues being a major public health problem worldwide. Thus, future research efforts are
direly needed - also for the rarer tumor types. Although obtaining samples of a rare tumor type is not
an easy task, these cancers affect many people and such studies can also help understanding the more
common diseases. In the future, the aim is to improve utilization of cancer genomes for individualized
therapeutic decisions, such as the ability to predict prognosis, to choose correct combinatorial
treatment regimen that has efficacy for a particular genetic subtype, to be able to monitor therapy
responses, and to identify drug-resistant subclones. Expanding information also on genetic
predisposition, environmental exposures, and their combined effects provides means for better cancer
risk assessment. It is imperative to improve understanding of the complex biology underlying tumor
evolution to direct future efforts of reducing cancer burden through prevention and more efficient
care - and to ultimately improve patients’ outcome.
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